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ABBREVIATIONS 
 
AD         Alzheimer‟s Disease 
NFTs     Neurofibrillary tangles 
EOAD   Early onset Alzheimer‟s Disease 
LOAD   Late onset Alzheimer‟s Disease 
FAD    Familial Alzheimer‟s disease 
APP    Amyloid Precursor Protein 
PS-1    Presenilin-1 
PS-2   Presenilin-2 
apoE   Apolipoprotein E 
MCI    Mild Cognitive Impairment 
CSF    Cerebrospinal fluid 
PET    Positron-emission tomography 
p-tau  Phosphorylated-tau  
MRI    Magnetic Resonance Imaging 
SPECT  Single-Photon Emission Computed Tomography 
GFAP  Glial Fibrillary Acidic Protein 
APPsβ  Ectodomain of APP  
βCTF or C99 APP Carboxy-Terminal Fragment 
BACE  β-site APP cleaving enzyme 
αCTF or C83 APP Carboxy-Terminal Fragment 
AICD  APP Intracellular Domain 
LTP   Long Term Potentiation 
MAPT  Microtubule-Associated Protein Tau 
CNS   Central Nervous System 
PNS   Peripheral Nervous System 
PHF   Paired Helical Filaments 
MTL   Medial Temporal Lobe  
NMDA  N-methyl-D-aspartate 
AMPA  2-amino-3-(3-hydroxy-5-methylisoxazol-4-yl)  
propanoic acid 
ROS   Reactive Oxygen Species 
GFAP  Glial Fibrillary Acidic Protein 
IL-1β   Interleukin-1β 
TNF-α  Tumor Necrosis Factor-α 
IFN-γ  Interferon-γ 
Ca2+   Calcium 
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ER   Endoplasmic Reticulum 
ATP   Adenosine triphosphate 
mPTP  Mitochondrial Permeability Transition Pore 
CytC   CytochromeC 
PDGF  Platelet-Derived Growth Factor 
PrP   Prion Protein 
FTDP-17 Frontotemporal Dementia And Parkinsonism 
Linked To Chromosome 17 
KV Voltage Gated Potassium Channels 
ER Endoplasmic Reticulum 
KChip K+ Channel Interacting Proteins 
KChAP K+ Channel Associated Protein 
DPPLs Dipeptydil Aminopeptidase Like Proteins 
MinK Minimal K+ currents 
MiRPs MinK-related peptides 
PC-12 Pheochromocytoma Cells 
TEA Tetraethylammonium 
4-AP 4-aminopyridine 
BDS-I Blood Depressing Substance I 
BDS-II Blood Depressing Substance II 
[K+]I Intracellular Potassium Concentrations 
HPLC High Performance Liquid Chromatography 
HFIP 1,1,1,3,3,3-Hexafluoro-2-Propanol 
IP Immunoprecipitation 
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SUMMARY 
Voltage gated potassium channels (KV) play a pathogenetic role in many 
neurodegenerative disorders, including Alzheimer‟s Disease (AD). Recently, it 
has been demonstrated that hippocampal neurons and NGF-differentiated PC-
12 cells exposed to Aβ1–42 display a selective over-expression and increased 
activity of KV3.4 potassium channels. The goal of this study has been to further 
investigate the role of KV3.4 channels in a transgenic mouse model of AD, 
Tg2576. Firstly, we observed an over-expression of KV3.4 and its accessory 
subunit MiRP2 in the hippocampus of young Tg2576 mice (3 months old), 
whereas no significant modification was observed in elderly Tg2576 mice (14-
18 months old). Moreover, Tg2576 hippocampal neurons showed an early 
increase in KV3.4 channel activity These data suggested that KV3.4 up-
regulation play a critical role in the early stages of AD, since it contributes to 
neuronal hyperexcitability induced by the accumulation of Aβ1-42 dimers and 
trimers occurring in these stages. The immunocytochemical analysis showed 
that the early increase in KV3.4 expression was accompanied by an altered 
subcellular distribution of this protein in Tg2576 hippocampal neurons, in 
particular we observed a more intense KV3.4 immunosignal localized to the 
soma plasma membrane. Intriguingly, the over-expression and increase 
activity of KV3.4 in young Tg2576 mice were accompanied by the activation of 
caspase-3. Moreover, the KV3.4 silencing in vivo by intracerebroventricular 
injection, not only strongly reduced KV3.4 expression but also prevented 
caspase-3 activation. Interestingly, siKV3.4 reduced the Aβ1-42 trimers levels in 
the same young Tg2576 mice suggesting the possible indirect link between 
KV3.4 over-expression, caspases activation and Aβ1-42 trimers deposition. 
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Several studies showed that Aβ1-42 trimers are closely related to memory 
impairment occurring in the early stages of AD. Our studies performed by T-
maze spontaneous alternation test indicated that Tg2576 mice (3 months old) 
exhibited the impairment of exploration ability, spatial learning and memory 
abilities. Interestingly, Tg2576 mice in the presence of siKV3.4 displayed the 
amelioration in exploration ability and memory performance. Furthermore, the 
Open Field test showed that Tg2576 mice (3 months old) were hyperactive 
since they travelled a greater average distance compared to Wild Type mice. 
Attractively, Tg2576 in the presence of siKV3.4 displayed a reduction in the 
distance traveled compared to Tg2576 mice in the absence of siKV3.4. 
Collectively, these data proposed that the inhibition of KV3.4, ameliorating 
memory performance and non-cognitive symptoms, could become a new 
pharmacological target in the care of AD. To this aim we tested a new 
synthetic compound, BDS1-8, containing the first eight aminoacids from full 
lenght BDS-I, a well known KV3.4 inhibitor. BDS1-8 was able to prevent both 
increased KV3.4 activity and caspase-3 activation induced by Aβ1–42 oligomers. 
At last, we observed an up-regulation of KV3.4 and GFAP protein expression 
in primary astrocytes exposed to Aβ1-42 peptide. Interestingly, coexpression 
and co-immunoprecipitation studies revealed a large overlap and a direct 
binding of KV3.4 with GFAP. Moreover, the in vivo siKV3.4 significantly down-
regulated GFAP in Tg2576 mice (3 months old) confirmig the closely link 
between GFAP and KV3.4. These data suggested that GFAP might promote 
channel trafficking in precise membrane domains faciliting the accumulation of 
KV3.4 channel, in order to modulate cellular mechanisms mediated by K
+ ions. 
Collectively, our data suggest a critical role of KV3.4 in Aβ oligomers effects on 
neuron excitability, astrocytes activation and cognitive functions in AD.
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Chapter 1: Alzheimer’s Disease 
 
1.1 Epidemiology 
AD is the most common neurodegenerative disorder in the aging population. It 
is characterized by cognitive impairment, progressive degeneration of 
neuronal populations and formation of amyloid plaques composed of amyloid 
β (Aβ) deposits and neurofibrillary tangles (NFTs) (Selkoe, 2001). AD is 
named by Alois Alzheimer, a Bavarian psychiatrist, who in 1907 first reported 
the case of a middle aged woman who developed memory deficits and 
cognitive impairments (Alzheimer, 1907). After the Alzheimer‟s description, for 
a long time, little progress has been achieved in defining AD pathogenesis. 
This situation began changing in the 1960s, when the advent of electron 
microscopy allowed to describe the ultrastructural changes underlying the two 
classical lesions which Alzheimer had linked: senile plaques and NFTs 
(Selkoe, 2001). Parallel to these neuropathological modifications, various 
neurotransmitter systems are altered in the brain tissues of subjects with AD 
(Quirion, 1993). In the mid-1970s was observed a reduction in neurons 
synthesizing and releasing acetylcholine. In particular, was found a reduction 
in the amounts and activities of two specific enzymes: choline 
acetyltransferase and acetylcholinesterase (Selkoe, 2001). After the 
pioneering work of Davies and Maloney (1976), various groups (Perry et al., 
1977; Coyle et al., 1983; Etienne et al., 1986; Perry et al., 1986) reported 
about the alteration of cortical and hippocampal cholinergic projections in AD. 
In the late 1970s, were identified deficits of other neurotransmitter systems in 
AD brain tissue (Greenwald, 1983; Davies P, 1983). It became progressively 
more clear that AD did not involve degeneration of a single transmitter class of 
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neurons but was highly heterogeneous (Nordberg, 1993). In 2006 the 
worldwide prevalence of dementia is as high as 26 million, and it was 
predicted that the percentage of cases will grow fourfold to 106.8 million by the 
year 2050 (Reitz and Mayeux, 2014). Approximately, 4.6 million new cases 
were recognized every year (Ferri et al., 2005), about 70% of these cases 
were attributed to AD. The incidence of dementia increases exponentially with 
age, the most prominent increase occurs during the 7th and 8th decades of 
life. Based on its age of onset, AD is classified into early onset AD (EOAD, 
onset < 65 years) around for 1–5% of all cases, and late-onset AD (LOAD, 
onset ≥ 65 years) around for >95% of affected. EOAD have a definite genetic 
element, they are inherited in an autosomal dominant manner (McDowell, 
2001). Genetic linkage analyses have led to the identification of three genes 
associated with familial AD (FAD): Amyloid β-Protein Precursor (APP) on 
chromosome 21 (Goate et al., 1991), presenilin-1 (PS-1) on chromosome 14 
(Sherrington et al., 1995), and presenilin-2 (PS-2) on chromosome 1 (Rogaev 
et al., 1995). The vast majority of AD cases occur in sporadic form after 65 
years of age, lacking alterations in the known set of genetic markers, which 
suggests either environmental causes or a combination of environmental and 
genetic factors. Nevertheless, the sporadic late-onset cases of AD also have a 
genetic component as the apolipoprotein E (apoE) gene in chromosome 19 
(Strittmatter et al., 1993). Previous evidence of the involvement of 
chromosome 19 has been confirmed by the finding of an association between 
AD and the apoE on chromosome 19. apoE has three alleles: apoE-ε2, apoE-
ε3, and apoE-ε4. A total of 80% of familial and 64% of sporadic AD late onset 
cases have at least one apoE-ε4 compared to 31% of control subjects. This 
 8 
 
finding implicates apoE-ε4 as an important factor in the etiology of AD (Corder 
et al., 1993). 
 
1.2 Clinical features of Alzheimer‟s disease 
The disease often begins as a syndrome termed mild cognitive impairment 
(MCI), which is usually characterized by a memory complaint and impairments 
on formal testing, intact general cognition, preserved daily activities and 
absence of explicit dementia. MCI is considered as a transitional stage 
between normal aging and early AD. The clinical manifestations of 
symptomatic AD include increasing difficulties with memory and with other 
cognitive functions (executive functions, language, attention, judgment, etc). In 
the late stages of AD, mental functions and activities of daily living are 
increasingly impaired and patients become profoundly demented (Basic 
Neurochemistry, George J. Siegel, 2005). People with AD, at the beginning of 
the disorder, do not seem to have any difficulty remembering distant events 
but may, for example, forget having done something five minutes ago. The 
earliest cognitive deficit seems to be the impairment of episodic memory (the 
ability to recall events that are specific to a time and place). In addition to the 
changes that occur in memory and cognitive abilities, people with AD have 
additional symptoms that impair vision (agnosia), speech (aphasia) and motor 
function (apraxia). Agnosia is the inability to interpret vision accurately and to 
process sensory information. Agnosia is also described as loss or diminution 
of the ability to recognize objects, sounds, smells, tastes, or other sensory 
stimuli. Aphasia is the inability to use and interpret language appropriately; it 
impairs the production or comprehension of speech and the ability to read or 
write. Apraxia is the inability to perform familiar movements on command; it is 
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a disorder of motor planning. Impairment of other cognitive functions becomes 
increasingly prominent during the course of the disease. As the pathology 
spreads to involve cortical association areas, this gives rise to a dementia 
syndrome that is characterized by deficits in attentional and executive 
functions (a cluster of high-order capacities, which include selective attention, 
behavioral planning and the manipulation of information in problem-solving 
tasks), in semantic memory (word, face and object knowledge), in language, 
praxis, and in constructional and visuospatial abilities (Nestor et al., 2004). 
The loss of procedural memory induces difficulties in routine activities such as 
dressing, washing and cooking. In AD patients are evident emotional 
problems, such as anxiety, paranoia, frustration or irritability, hallucinations, 
anger, aggression or hostility. 
 
1.3 Diagnosis of Alzheimer‟s disease 
Criteria for the clinical diagnosis of AD were established in 1984. The criteria 
are proposed as a guide for the diagnosis of probable, possible, and definite 
AD (McKhann et al, 1984). AD dementia is characterized by progressive 
impairment of memory and other cognitive functions. Neuropsychological tests 
provide positive evidence of the diagnosis of dementia and help to assess the 
course and response to therapy. The doctor will interview the person being 
tested and others close to him or her to collect information about recent and 
past mental and physical illnesses. The doctor will assess mental status, 
memory, the ability to solve simple problems and other thinking skills. 
Moreover all cognitive tests are sensitive to differences in age, education and 
cultural variation among individuals (Albert et al., 2011). Recently, criteria for 
the clinical diagnosis of AD established in 1984 have been improved through 
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the integration of biomarkers to evaluate disease state. Biomarkers are 
parameters (physiological, biochemical, anatomic) that can be measured and 
that reflect specific features of disease related to pathophysiological 
processes (Clifford et al., 2011). Some biomarkers directly reproduce the 
pathology of AD. Evidence suggests that both Aβ deposition and elevated 
tau/phosphorylated tau are biomarkers of AD. The biomarkers of Aβ 
accumulation include both cerebrospinal fluid (CSF) measures of lower Aβ1-42 
levels and positron-emission tomography (PET) evidence of Aβ deposition, 
using a variety of specific ligands. The biomarkers of tau accumulation include 
CSF measures of increased total tau or phosphorylated-tau (p-tau). Therefore, 
the two biomarkers in combination are really clarifying. Moreover, for an 
accurate diagnosis of AD it is also necessary to evaluate neuronal injury, 
through a number of structural and functional measures, including brain 
atrophy, and hypometabolism or hypoperfusion obtained with magnetic 
resonance imaging (MRI), PET, and single-photon emission computed 
tomography (SPECT) imaging. 
 
1.4 Neuropathological alterations in Alzheimer „s Disease 
The typical lesions of AD are the extracellular deposits of Aβ in parenchymal 
plaques, vascular amyloid and the intraneuronal NFTs (Fig 1B) (Serrano-Pozo 
et al., 2011). Those classical lesions are accompanied by astrogliosis 
(Verkhratsky et al., 2010) and microglial cell activation that can cause or 
aggravate neuron damage (Li et al., 2014). Generalized astrogliosis, 
manifested by cellular hypertrophy and by an increase in expression of glial 
fibrillary acidic protein (GFAP) and astroglial S100B protein, was routinely 
observed in postmortem tissues from AD patients (Nagele et al., 2004). The 
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activated astrocytes are closely involved in the neuroinflammatory component 
of AD through the release of cytokines, proinflammatory factors, and nitric 
oxide/reactive oxygen species neurotoxicity (Heneka et al., 2010). 
Furthermore it is known the correlation between the degree of astrogliosis and 
cognitive decline. 
 
 
Fig.1 Alzheimer‟s disease pathology. (A) Healthy brain versus Alzheimer‟s disease brain. 
(B) Neuropathological hallmarks of Alzheimer‟s disease: Amyloid Plaques and Neurofibrillary 
Tangles (NFTs). 
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1.4.1 Amyloid pathology 
Neuritic plaques, one of the two brain lesions observed in Alzheimer‟s original 
patient, are microscopic foci of extracellular amyloid deposition. Much of the 
fibrillar Aβ found in the neuritic plaques is the species ending at aminoacid 42 
(Aβ42), the slightly longer, more hydrophobic form that is particularly prone to 
aggregation. Aβ deposits are also observed in normal aging individuals, but at 
a lower density (Perry et al, 1978). The "amyloid hypothesis" suggests that the 
accumulation of Aβ fragments 1–40 and 1–42 is primarily responsible for AD 
pathology, and the imbalance of Aβ production and Aβ clearance induces the 
cognitive impairments associated to AD (Jacobsen et al., 2006). According to 
the amyloid hypothesis of AD, the overproduction of Aβ is a consequence of 
the disruption of the process that regulate the proteolytic cleavage of the APP 
(De-Paula et al., 2012). Biologic studies have shown that AD-causing 
mutations in APP and in presenilin-1 (PS1) or PS2 enhance the production of 
the Aβ42 peptide. The improved production of the Aβ42 peptide results in an 
increase in Aβ42 levels, or in an increase in the Aβ42/Aβ40 ratio. Aβ42 peptide 
with its C-terminal alanine and isoleucine residues is more hydrophobic and 
aggregates more rapidly than Aβ40 peptide (Haas and Selkoe, 2007). 
Moreover the neurotoxic potential of the Aβ peptide results from its 
biochemical properties that promote aggregation into insoluble oligomers and 
protofibrils. These fibrillary Aβ species accumulate into senile and neuritic 
plaques. These processes, accompanied to reduction of Aβ clearance from 
the brain, leads to the extracellular accumulation of Aβ, and the consequent 
activation of neurotoxic cascades that ultimately lead to cytoskeletal changes, 
neuronal dysfunction and cellular death. Aβ peptide is derived by sequential 
proteolytic processing from a large type I trans-membrane protein, the APP 
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that is present in several cell types, including neurons and astrocytes. The 
function of the APP remains not fully understood, although several studies 
have demonstrated a number of its putative physiological roles. The APP 
extracellular domain could function as a cell surface receptor; could have a 
role in cell-substratum adhesion and in neurite outgrowth and synaptogenesis 
(Zheng et al., 2006). Furthermore the APP intracellular domain could be 
involved in cell migration, synapse remodeling and cell signaling (Zheng et al., 
2006). The proteolytic enzymes involved in APP processing are named 
secretases: α, β, and γ (Haass et al., 2004). The name “secretases” refers to 
the secretion of the proteolytically cleaved substrates. There are two different 
pathways to process APP: the amyloidogenic pathway, which leads to Aβ 
generation; and the non-amyloidogenic pathway, which prevents Aβ 
generation. In the amyloidogenic pathway the cleavage of APP is mediated 
from the consecutive action of β- and γ-secretase producing Aβ peptide 
(Haass et al., 2004). The β-secretase cuts a large part of the ectodomain of 
APP (APPsβ), generating an APP carboxy-terminal fragment (βCTF or C99), 
which is then cleaved by γ-secretase. β-secretase, also known as β-site APP 
cleaving enzyme (BACE1 and 2), is considered the enzyme that controls the 
Aβ production, and BACE-directed therapy is currently one of the aims of 
several researches (Yan and Vassar, 2014). At the end of the amyloidogenic 
pathway, Aβ is released and then found in extracellular fluids such as plasma 
or cerebrospinal fluid. In the non-amyloidogenic pathway, APP is cleaved in 
the middle of the Aβ region by the α-secretase activity. This processing 
generates a truncated APP CTF (αCTF or C83). The successive 
intramembrane cut by γ-secretase liberates a truncated Aβ peptide called p3. 
Furthermore γ-Secretase not only liberates Aβ (from C99) and p3 (from C83) 
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but also generates the APP intracellular domain (AICD) which is released into 
the citosol (Fig. 2). Aβ is produced as a monomer, but quickly aggregates to 
form multimeric complexes, from low molecular weight dimers and trimers to 
higher molecular weight protofibrils and fibrils (LaFerla et al., 2007). 
Protofibrils are transient structures which appear earlier to the formation of 
mature amyloid fibrils and can be named prefibrillar aggregates. The 
oligomeric species of Aβ exert a pathological role compromising cognition, 
learning and memory, synaptic function and long term potentiation (LTP) 
(Walsh et al., 2002). The Aβ peptide was first identified as a component of 
extracellular amyloid plaques; but in the last years a large number of studies 
have demonstrated the presence of intracellular Aβ, that also plays a 
pathophysiological role in the progression of AD. In the first study reporting the 
presence of intraneuronal Aβ, an antibody against residues 17–24 of Aβ was 
used, and Aβ-immunoreactive material was observed in neurons from the 
brain and spinal cord of individuals with or without AD (Grundke-Iqbal et al. 
1989). Several studies, in various transgenic models of AD, indicated that Aβ 
may accumulate intracellularly and that memory impairments precede the 
accumulation of extracellular plaques (Oddo et al., 2006). The accumulation of 
intraneuronal Aβ is an early event in the AD progression, preceding the 
formation of extracellular Aβ deposits. Indeed, it has been demonstrated that 
intraneuronal Aβ levels decrease as extracellular plaques accumulate (Mori et 
al. 2002). Evidence suggests that intracellular Aβ may contribute to pathology 
by facilitating tau hyperphosphorylation, disrupting proteasome and 
mitochondria function, and triggering calcium and synaptic dysfunction 
(LaFerla et al., 2007). Three clinical phases of AD may be defined: 1) pre-
symptomatic (or pre-clinical) AD, which may last for several years or decades 
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in which the overproduction and accumulation of Aβ in the brain reache a 
critical level that triggers the amyloid cascade; 2) pre-dementia phase of AD 
(compatible with the phase of MCI), in which early-stage pathology is present; 
3) clinically defined dementia phase of AD, in which cognitive and functional 
impairment is severe: at this stage there is significant accumulation of neuritic 
plaques and neurofibrillary tangles (De-Paula et al., 2012).  
 
 
Fig.2 APP proteolytic cleavage. The amyloid precursor protein (APP) is a transmembrane 
protein that can undergo a series of proteolytic cleavages by secretase enzymes. When it is 
cleaved by α-secretase and γ-secretase enzymes, the cleavage is not amyloidogenic. Instead, 
when APP is cleaved by β- and γ-secretase enzymes, neurotoxic Aβ peptides are released 
and  accumulate into oligomers aggregate. 
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1.4.2 Neurofibrillary tangles  
Tau (tubulin-associated unit) is a low molecular weight protein, which 
displayed the ability to promote microtubule assembly and stability 
(Weingarten et al., 1975); it is found in both neuronal and non-neuronal cells, 
but predominating in neurons (Rossi et al., 2008). In addition to the functions 
already known, tau is involved in the maintenance of axonal transport of 
vesicles and organelles and in providing linkage for signal transduction (Buee 
et al., 2000). Tau is a product of the microtubule-associated protein (MAPT) 
gene, located on chromosome 17 (Neve et al., 1986). The tau gene, through 
complex post-transcriptional processing, produces three transcripts: a less 
abundant 2kb tau transcript which encodes for a tau principally targeted to the 
nucleus; 6kb transcript which encodes for tau predominantly directed to the 
soma/axons in the central nervous system (CNS); 8/9 kb transcript producing 
a tau specially expressed in the retina and peripheral nervous system (PNS). 
The tau molecule is subdivided into four regions: N-terminal acidic region, 
Proline-rich region/domain, repeat domain region and C-terminal region 
(Maina et al., 2016). The adult brain expresses six isoforms of tau, which 
derive from alternative mRNA splicing and differ by the presence of three or 
four tubulin binding domains (repeats) of 31 or 33 aminoacids in the C-
terminal portion, and none, one or two inserts in the N-terminal region. Tau, 
mostly in a dephosphorylated state, has been localized in the plasma 
membrane of different cells; its N-terminal domain mediates the interaction 
with the plasma membrane (Buee et al., 2000). Interestingly, this tau-
membrane interaction is highly dynamic and depends on phosphorylation. 
Hyperphosphorylation of tau, its aggregation in paired helical filaments (PHF) 
and NFTs in vulnerable neurons are one of the hallmark of AD (Martin et al., 
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2011). Tau pathology, is also seen in several other human neurodegenerative 
disorders, called tauopathies. In everyone of these disorders the accumulation 
of the abnormally hyperphosphorylated tau is associated with neurofibrillary 
degeneration and dementia. The abnormal hyperphosphorylation of tau 
precedes its accumulation in the affected neurons in AD. The abnormally 
hyperphosphorylated tau was discovered not only in neurofibrillary tangles but 
also in cytosol from AD brains. Quantitative immunocytochemical studies have 
revealed deposits of only abnormally phosphorylated tau, but not normal tau, 
in neurons without tangles. These results suggest that the abnormal 
hyperphosphorylation of tau precedes its accumulation into neurofibrillary 
tangles (Bancher et al., 1989). The abnormally hyperphosphorylated tau is 
found in AD brain in two different pools: as polymerized into neurofibrillary 
tangles and as non-fibrillized form in the cytosol. Since the abnormal filaments 
are highly insoluble, NFTs remain in the extracellular space following the 
complete degeneration of the affected neuron and become extracellular 
“ghost” tangles. The abnormally hyperphosphorylated tau not only is unable to 
stimulate microtubule assembly and to bind microtubules, but also sequesters 
normal tau, inhibits the assembly and disrupts the microtubules. The 
impairment of the microtubule network in the affected neurons compromises 
axonal transport, leading to retrograde degeneration which, in turn, results in 
dementia (Iqbal et al., 2004). 
 
1.5 Braak staging 
The deposition of Aβ1-42 peptide and the development of neurofibrillary tangles 
are important histopathological hallmarks of AD. In the Braak staging, the 
medial temporal lobe (MTL) serves as a model to evaluate the changes in the 
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anatomical distribution of different types of Aβ-deposits occurring in the course 
of AD, as well as to assess the relationship between the development of Aβ-
deposition and neurofibrillary pathology (Thal et al., 2000). In the first of 4 
phases of β-amyloidosis there are diffuse non-neuritic plaques in the basal 
temporal neocortex, while the hippocampus is lacking of Aβ. The same Aβ 
deposits type appears in the second phase within the external entorhinal 
layers, in the internal entorhinal layers and in the hippocampal sector CA1. In 
addition to the regions involved in phase 2, in the third phase, Aβ-deposits 
appear in the molecular layer of the fascia dentata, in the molecular layer of 
both the entorhinal region and the temporal neocortex. In addition, Aβ-
deposits appear in the parvopyramidal layer of the presubicular region of the 
cortex. In hippocampal sector CA1 the number of plaques has increased 
predominantly in the superficial pyramidal layer. The fourth phase is 
characterized by diffuse plaques in the hippocampal sector CA4 (Braak and 
Braak, 1991). Furthermore, NFTs exhibit a characteristic distribution pattern 
permitting the differentiation of six stages. A hierarchical staging system for 
the neuropathological changes in AD has been elaborated following the 
distribution of NFTs (Braak and Braak, 1994). In stages I and II (the 
transentorhinal stages), NFTs are restricted to the entorhinal cortex and the 
CA fields of hippocampus. Stages III and IV (the limbic stages) are 
characterized by moderate numbers of NFTs in the hippocampus, basolateral 
amygdala, and limbic nuclei of the thalamus. In stages V and VI (the 
isocortical stages) all hippocampal subfields and isocortical association areas 
are severely affected.  
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1.6 Hypothesis of Alzheimer‟s Disease pathogenesis 
During the past decades various hypotheses have been suggested to explain 
the molecular pathogenesis of AD, of which the principal are the “amyloid 
cascade hypothesis” and the “tau and tangle hypothesis”. 
  
1.6.1 Amyloid cascade hypothesis 
The amyloid cascade hypothesis postulates that the deposition of Aβ peptide 
in the brain parenchyma starts a sequence of events that culminate with AD 
dementia (Fig. 3). Aβ levels can be elevated by enhanced production and/or 
reduced clearance. In particular, the Aβ42/Aβ40 ratio can be increased by 
mutations in three different genes (APP, PS1 and PS2) that cause familial 
forms of AD. This increase of Aβ42 enhances oligomers formation, which 
causes severe and permanent changes of synaptic function. Furthermore, the 
deposition of Aβ42 in the brain parenchyma induces local inflammatory 
responses (microgliosis and astrocytosis), synaptic spine loss and neuritic 
dystrophy. Collectively, these events result in oxidative stress, altered ionic 
homeostasis and additional biochemical changes. Moreover, NFTs are 
induced by altered kinase and phosphatase activities and contribute to 
additional defects, including some in axonal transport. The cascade 
culminates in synaptic/neuronal dysfunction and cell death, leading to 
progressive dementia (Haass and Selkoe, 2007; Karran et al., 2011). 
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Fig.3 Amyloid Cascade hypothesis. The deposition of Aβ peptide in the brain is a 
central event in AD pathology triggering a sequence of events that culminate with AD 
dementia. 
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1.6.2 Tau hypothesis 
The tau hypothesis of AD pathogenesis proposes that dysregulation of tau 
phosphorylation, misfolding, subsequent aggregation of tau and tau 
fibrillization may play a significant role in synaptic and neuronal loss. 
Aggregation of altered tau produces different effects at various stages of AD. 
Interestingly, in early stages of AD, the loss of normal tau function may pilot 
neurodegeneration. Therefore, in the progression of the disease, toxic effects 
of tau aggregates may accelerate the neurodegeneration. Misfolded, truncated 
tau protein promotes activation of microglia and leukocyte infiltration in the 
transgenic model of tauopathy. Tau-mediated neurodegeneration may occur 
through neuroinflammatory processes, impaired axonal transport, oxidative 
stress, or a combination of these processes. As support for the central role of 
tau aggregation, tauists assert that the cognitive decline in late stages of AD 
has a strong correlation with tangle formation, whereas it weakly correlates 
with Aβ burden. However, since in non-AD tauopathies tau proteins 
aggregation occurs in the absence of Aβ deposition, it is likely that tangles are 
not sufficient to induce amyloid plaques in AD. In fact, although Aβ aggregates 
and NFTs are the hallmarks of AD, they don‟t develop temporally in parallel in 
human brain and NFTs arise only after Aβ accumulation. A transgenic mouse 
model overexpressing both mutant APP and mutant tau has both plaques and 
tangles (Lewis et al, 2001). Interestingly, the double mutant has more tangles 
than tau-mutant mice alone and tangles appear in brain areas that are 
unaffected in single mutant-tau transgenic mice. In a parallel experiment 
another group showed that injection of amyloid into the cerebrum of mutant 
tau transgenic mice exacerbated tangle pathology (Gotz et al, 2001). These 
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models together demonstrate that tangles and plaques are linked 
pathogenetically. 
 
1.7 Changes in ionic homeostasis in Alzheimer‟s Disease 
Sodium (Na+) and potassium (K+) ions are critical for “nerve impulses" or 
"spikes", membrane transport, and other cellular processes. In neurons, action 
potentials play a central role in cell-to-cell communication and are generated 
by transmembrane voltage-gated ion channels. At the beginning of the action 
potential, the opening of Na+ channels allow an inward flow of Na+ ions, which 
changes the electrochemical gradient, causing depolarization. Repolarization 
occurs with the opening of K+ channels; there is an outward current of K+ ions, 
that induce the return of the electrochemical gradient to the resting state. 
Changes in brain Na+ and K+ ion homeostasis in AD are a recent finding. 
Vitvitsky et al., measured Na+ and K+ concentrations in postmortem brain 
samples of AD individuals and age-matched controls. In AD samples they 
found Na+ increase of 20-25 %, and K+ increase of 15% (Vitvitsky et al., 2012; 
Graham et al., 2015). 
 
1.7.1 Calcium dysregulation and excitotoxicity 
Calcium (Ca2+) is one of the most important intracellular messengers in the 
brain, it is essential for neuronal development, synaptic transmission and 
plasticity, and for the regulation of various metabolic pathways. The regulation 
of Ca2+ concentration in neuronal cells is very complex, involving proteins 
localized on the plasma membrane, cytosol, mitochondria, and endoplasmic 
reticulum (ER). Several evidence suggested that calcium also plays a 
prominent role in the pathogenesis of AD (Mattson and Chan, 2001) and that 
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Aβ peptide can induce an increase of intracellular calcium levels causing 
excitotoxicity (Mattson and Chan, 2003). The Ca2+ hypothesis of AD suggests 
that the deleterious effects of Aβ peptide depend on the dysregulation of Ca2+ 
signaling (LaFerla 2002). The general notion is that abnormal amyloid 
metabolism induces an upregulation of neuronal Ca2+ signaling that is 
responsible for the initial decline in memory and subsequent apoptosis. 
Therefore, Ca2+ plays important roles in synaptic plasticity by its actions at 
both pre- and postsynaptic terminals. In addition, there is increasing evidence 
that Aβ peptide also acts on microglial cells and astrocytes (Saijo & Glass, 
2011) to induce local inflammatory response that contributes to Ca2+ signaling 
deregulation. Aβ peptide can promote Ca2+ influx by forming calcium-selective 
channels in membranes or by activating cell surface receptors coupled to 
calcium influx (Mattson and Chan, 2003). In addition, Aβ peptide impairs 
membrane calcium pumps and enhances calcium influx through voltage-
dependent channels and ionotropic glutamate receptors. Thus, it‟s necessary 
to find a new therapeutic approach in order to stabilize intracellular Ca2+ 
homeostasis. 
  
1.8 Mitochondrial dysfunction 
Mitochondria, the major organelles in neurons, produce energy as adenosine 
triphosphate (ATP). Other functions of mitochondria are: the regulation of 
calcium homeostasis and apoptotic mechanisms, the generation of free 
radicals. More evidence have indicated that mitochondrial dysfunction involves 
alterations of mitochondrial respiratory chain enzymes, generation of ROS, 
opening of mitochondrial permeability transition pore (mPTP), structural 
abnormalities of mitochondria, oxidative stress and apoptosis (Hauptmann et 
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al., 2006). These mitochondrial abnormalities are identified early in AD, before 
Aβ deposition, and are related to Aβ or tau pathology (Swerdlow et al., 2010). 
In 2004, Swerdlow and colleagues have proposed the paradigm of 
"mitochondrial cascade hypothesis" (Swerdlow et al., 2004). This hypothesis 
supposed that FAD and sporadic AD are not etiologically same (Swerdlow et 
al., 2014). In FAD, excessive Aβ accumulation slowly impairs mitochondrial 
functions which further initiate other AD related pathologies such as oxidative 
stress or neuroinflammation. In sporadic AD, age related occurrence of 
mitochondrial dysfunctions causes a variety of pathologies including oxidative 
stress and apoptosis. Aβ peptide accumulation in mitochondria causes: the 
inhibition of mitochondrial respiratory enzyme complex-II and IV; a decrease in 
ATP production; an increase in ROS production (Swerdlow et al., 2010). 
Further, Aβ peptide overproduction leads to dysfunctioning of mitochondrial 
Ca2+ channels and enhancement of cytochromeC (CytC) release (Caspersen 
et al. 2005). It has also been reported that Aβ peptide accumulation causes 
abnormal expression of mitochondrial proteins which are involved in 
mitochondrial fission and fusion machinery, causing abnormal mitochondrial 
morphology and mitochondria degradation (Manczak et al., 2011). In 
conclusion, alteration in mitochondrial bioenergetics, mitochondrial dynamics, 
mitochondrial trafficking and oxidative stress play a key role in AD. Thus, 
therapeutic strategies in AD are wanted to target mitochondrial dysfunction, to 
enhance mitochondrial bioenergetics or to reverse oxidative stress. 
 
1.9 Synaptic Degeneration in Alzheimer‟s Disease 
Studies performed in human brains and in vivo and in vitro models support the 
concept of the synapse failure during AD. Synaptic dysfunction occurs early, 
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followed by pre-synaptic and spine loss, axonal dystrophy and neuronal loss 
(Overk and Masliah, 2014). Therefore, patients with MCI display loss of pre-
synaptic proteins such as synaptophysin, VAMP2, and SNAP25 and post-
synaptic markers such as PSD95 and Shank1 (Pham et al., 2010). The 
memory impairment in AD patients correlates with synaptic loss in the 
neocortex and limbic system (DeKosky et al., 1990). In contrast, cognitive 
impairment does not correlate with Aβ plaques in the brain. In AD the loss of 
synapses is higher than the neuronal loss, suggesting that synaptic damage 
precedes the loss of neuronal cell. Recent studies have highlighted that Aβ 
oligomers might be responsible for the synaptic damage and memory deficits 
(Lacor et al., 2007). Furthermore, Aβ oligomers once bound to synapses, can 
dysregulate the activity and reduce the surface expression of both N-methyl-D-
aspartate (NMDA) and 2-amino-3-(3-hydroxy-5-methylisoxazol-4-yl)-propanoic 
acid (AMPA) types of glutamate receptors, impairing signaling pathways 
involved in synaptic plasticity (Paula-Lima et al., 2013). Recent studies 
suggest an emerging role for Tau in the synaptic damage. It was been 
demonstrated that mice over-expressing human Tau display significant 
synaptic degeneration, suggesting that soluble Tau is synaptotoxic (Pooler et 
al., 2014). Interestingly, the Tau reduction with immunotherapy ameliorates 
behavioral deficits, synaptic dysfunction and network degeneration. The 
molecular mechanisms of synaptotoxicity of Aβ oligomers implicate: disruption 
of neuronal calcium homeostasis (De Felice et al., 2007; Paula-Lima et al., 
2011), oxidative damage to neurons (De Felice et al., 2007; Decker et al., 
2010), inflammatory processes (Bomfim et al., 2012; Ledo et al., 2012), 
mitochondrial fragmentation and dysfunction (Saraiva et al., 2010; Paula-Lima 
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et al., 2011), and disruption of fast axonal transport leading to synaptic 
dysfunction, synapse elimination and cell death (De Felice et al. 2007). 
 
1.10 Oxidative Stress  
Reactive oxygen species (ROS) are cytotoxic products of normal 
mitochondrial metabolism. Imbalance between mitochondrial ROS production 
and the intracellular levels of antioxidant leads to oxidative stress, a condition 
associated with apoptosis, inflammation, ischemia-reperfusion injury, and 
neurodegenerative diseases. The production of ROS plays a role in synaptic 
signaling, with ROS acting as messenger molecules in the process of LTP, a 
model for synaptic plasticity and learning. By contrast, abnormally elevated 
ROS levels have been implicated in the age-related impairment of LTP. Thus, 
elevated ROS levels in neurons can be detrimental as well as degenerative. 
Indeed exaggerated ROS levels are implicated in the molecular etiology of 
AD. In vitro studies indicate that cell exposure to Aβ oligomers leads to toxicity 
due to calcium influx, and to oxidative free radical damage. In fact Aβ 
oligomers stimulate a prominent increase in ROS formation through the 
activation of NMDA receptors, leading to a rapid increase in neuronal calcium 
levels. The dysregulation of ROS levels by Aβ oligomers may contribute to the 
early memory impairment in AD. These results provide a mechanistic link 
between activation of NMDA receptors, calcium influx, and ROS formation 
induced by Aβ oligomers. 
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1.11 Inflammation  
In AD brain, damaged neurons and neurites, insoluble amyloid β peptide 
deposits and NFTs provide evident stimuli for inflammation. Biochemical and 
neuropathological studies underlined an important relationship between 
inflammation and AD progression (Steardo et al., 2015). Indeed gliosis is a 
neuropathological feature in AD brains. 
 
1.11.1 Astrogliosis in Alzheimer‟s Disease 
In brain of AD patients, Aβ plaques are surrounded by reactive astrocytes and 
activated microglia. Nevertheless, the role of these activated glial cells 
remains still unknown. In AD conditions these cells undergo important 
morphological and functional changes and are considered to be involved in 
the onset and progression of the disease. Astrocytes are the most abundant 
and heterogeneous type of glial cells in the CNS. They are essential in the 
control of cerebral homeostasis (Verkhratsky and Butt, 2013), the main 
provider of glutamine to neurons and crucial players in the regulation of 
extracellular potassium (Halassa and Haydon, 2010). Moreover, astrocytes 
have an essential role in neuronal excitability (Halassa and Haydon, 2010) 
and synaptic function (Perea et al., 2014). In particular, they perceive neuronal 
and synaptic activity through activation of ion channels, neurotransmitter 
transporters and receptors (Perea et al., 2014). Astrocytes can regulate the 
activity of neurons and synapses by the uptake of neurotransmitters or by the 
release of gliotransmitters, contributing to neuronal network function (Perea et 
al., 2009). Astrocytes and neurons are in very close contact and they can 
communicate bidirectionally. To define the signaling between astrocytes and 
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neurons and to highlight the direct involvement of astrocytes in synaptic 
function, it has been developed a novel concepts of “tripartite synapse” 
(Araque et al., 1999). Interestingly, astrocytes play a protective role at tripartite 
synapse; they release antioxidants that protect neurons from oxidative stress 
and essential nutrients when demand is increased; they also take up excess 
of glutamate preventing glutamate toxicity. In AD, astrocytes undergo 
morphological and functional changes called astrogliosis. Astrogliosis is 
highlighted by increased glial fibrillary acidic protein (GFAP) expression. 
Interestingly, Aβ deposition is able to modify astrocytes physiological function. 
Thus, astrocytes may exhibit a “reactive” or “activated” phenotype 
(Verkhratsky et al., 2014). Activation of these cells is a protective response 
aimed at removing detrimental stimuli. In fact, the “reactive” state starts with 
the intention to control and remove the brain damage, however it has 
deleterious consequences. Indeed, reactive gliosis is a self-perpetuating 
process which, at the end, exacerbates the injury. Astrocytes, together with 
microglia, are the cellular component of the innate immunity in the CNS. They 
act as critical players of the neuroinflammatory response (Ransohoff and 
Brown, 2012). Several studies demonstrated that astrocytes possess tools to 
internalize and metabolize Aβ in vivo; they possess a complex apparatus able 
to take up Aβ (Wyss-Coray et al., 2003). Other studies reported that 
astrocytes could synthesize Aβ de novo (Zhao et al., 2011). In fact, astrocytes 
possess the necessary machinery to synthetize Aβ. APP and BACE1 
overexpression in astrocytes supports the notion that Aβ accumulation could 
be secondary to its production by activated astrocytes. Neuroinflammation 
usually involves the release from activated glia of neurotoxic molecules, 
including ROS, nitric oxide (NO), and pro-inflammatory chemokines and 
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cytokines such as interleukin-1β (IL-1β), tumor necrosis factor-α (TNF-α), and 
interferon- γ (IFN-γ). Excessive levels of these mediators are able to induce 
neuronal damage through a variety of mechanisms in AD. A limited number of 
studies investigated the effects of pro-inflammatory cytokine and Aβ 
stimulation on BACE1 and APP levels and β-secretase processing of APP in 
astrocytes. The effects of TNF-α and IFN-γ on Aβ production have been 
demonstrated in cultured cells including astrocytes (Blasko et al., 2000). By 
contrast, other studies have shown that Aβ itself is able to stimulate astrocytes 
to secrete pro-inflammatory molecules in vitro and in vivo (Zhong et al., 2007). 
In summary, astrocytes normally maintain and support the function of neurons; 
under inflammatory conditions they can contribute to the production of Aβ in 
the brain. Anti-inflammatory drugs that inhibit astrocytes activation and 
cytokine production (Combs et al., 2000) may also suppress the APP 
amyloidogenic pathway. 
 
1.11.2 Astrocytes and potassium homeostasis 
Astrocytes membranes have a high potassium conductance due to their 
abundant expression of potassium channels. Glial cells have the ability to 
maintain extracellular potassium concentration ([K+]e) at a constant level. This 
function has been called “K+-spatial buffering”, originally proposed by Orkand 
et al., 1966. They proposed the hypothesis that glia have a function to aspirate 
K+ ions at the sites where [K+]e is high to transport them within the cell, and to 
extrude the ions at the sites where [K+]e is low. Two conditions are necessary 
for optimal K+-spatial buffering: 1) the glial cells should form a syncytium in 
which K+ currents can cross relatively long distances; and 2) these cells 
should be highly and selectively permeable to K+. This mechanism minimizes 
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the deleterious effects of prolonged increases of [K+]e  resulting from neuronal 
activity. Thus, astrocytes modulate neuronal excitability and contribute to 
functions that depend on the transmembrane potassium gradient. To prevent 
undesirable neural excitation, glial cells aspirate excess extracellular K+ ions. 
 
1.12 Animal models of Alzheimer‟s Disease 
Animal models of AD must mimic the disease both pathologically and 
behaviorally. Janus et al proposed 5 expectations for a credible rodent model 
of AD: 1) mice should exhibit progressive neuropathology culminating in one 
or more of pathologic hallmarks of AD (plaques, NFTs); 2) mice should exhibit 
cognitive deficits evident in different behavioral paradigms targeting the same 
memory system; 3) in the case of experiments employing FAD mutations, 
phenotypic changes documented in 2 and 3 should be correlated with the 
presence of the FAD mutations; 4) key facets of the phenotype as for 1 and 3 
should be confirmed in independent transgenic lines harboring the same 
construct, to exclude the contribution of insertional mutations; 5) key facets of 
the phenotype as for 1 and 3 should have been confirmed in several 
laboratories. Several strains of transgenic mice overexpressing FAD-related 
mutated genes have been created. These animals show a variety of 
phenotypes that are similar to AD but none of them represent a full scene of 
AD. 
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1.12.1 APP transgenic mice 
Transgenic mice are created by expressing variants of APP, PS-1, PS-2, 
apoE, or tau genes. Mice that overexpress mutated forms of APP gene were 
the first transgenic models of AD. These mice develop a large variety of 
behavioral, biochemical, pathological, and physiological characters simulating 
AD, although not all characters have been represented within an individual 
mouse line. One of these models, the Tg2576 line, is used in the current study 
and its features will be discussed in detail in a separate section. The earliest 
transgenic models of AD overexpressed full-length (Lamb et al, 1993; Pearson 
et al, 1993) or C-terminal fragments (Kammesheidt et al, 1992) of wild-type 
APP (Mucke et al, 2000). Three different promoters (PDGF, PrP and Thy-1) 
and at least three mutations [V717I (Moechars et al, 1999), V717F (the 
PDAPP line, Games et al, 1995) and K670N/M671L (Hsiao et al, 1996)] 
produce age-dependent increases in Aβ concentration and deposition into 
amyloid plaques. However, none of these models share all the pathological 
changes seen in human AD. NFTs are absent in all these models, although 
hyperphosphorylated forms of tau are detectable. The severe loss of neurons 
and synapses, described in human AD, is not prominent in APP transgenic 
mice. In contrast, synaptic degeneration and dysfunction has been reported in 
all the models studied. Structural changes include reduced synaptophysin 
immunoreactivity, altered neurite path, dendritic spine loss and retreating of 
dendrites. Among the behavioural phenotype, hippocampal dysfunction is the 
earliest and most prominent feature of AD. Thus, behavioural testing of mouse 
AD models has focused on spatial learning and memory. APP transgenic mice 
model have been shown to develop deficits in spatial learning and memory in 
a variety of behavioural test (Hsiao et al, 1996; Jacobsen et al, 2006). 
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Interestingly, the severity of some behavioural deficits coincides with onset of 
amyloid deposition (Walsh et al, 2002). 
 
1.12.2 PS transgenic mice 
Mutations in PS-1 and PS-2 cause FAD. More than 170 mutations in PS-1 and 
14 mutations in PS-2 have been linked to FAD. Both PS-1 and PS-2 FAD 
mutant transgenic lines have been generated by pronuclear injection using a 
variety of heterologous promoter (Elder et al., 2010). These models only show 
increased production of Aβ42 without formation of neuritic plaques or neuronal 
loss. When crossed with plaque forming APP FAD mutant lines, the PS-1 FAD 
mutants cause earlier and more extensive plaque deposition. Although single 
transgenic PS-1 or PS-2 mice do not form plaques, they exhibit a number of 
pathological features including age-related neuronal and synaptic loss as well 
as vascular pathology. They also exhibit increased susceptibility to 
excitotoxicity injury most likely on the basis of exaggerated calcium release 
from the endoplasmic reticulum. Several studies have addressed the effects of 
PS-1 FAD mutants on electrophysiological parameters in hippocampal slice 
cultures. These studies revealed that PS-1 FAD mutants cause the 
enhancement of LTP in the hippocampus, but this effect appears to be age-
dependent and lost with aging. Some studies have evaluated whether PS FAD 
mutant transgenic mice display behavioral abnormalities using standard series 
of tests. PS FAD mutant mice have performed normally or the deficits have 
been inconsistent. Due to the lack of plaques, PS FAD mutant mice have been 
less studied than APP or APP/PS FAD mutant mice. 
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1.12.3 Tau transgenic mice 
The first tau transgenic models used expression of wild type four-repeat (Götz 
et al., 1995) and three-repeat (Brion et al., 1999) of human tau. These mice 
reproduced aspects of human pathology, such as hyperphosphorylation of tau 
protein. Although tau solubility decreases in age-dependent manner, these 
mice did not form NFTs, unless the mice reached a very old age (Ishihara et 
al., 2001). Later, many groups discovered pathogenic tau mutations for 
producing animal models. Following the identification of pathogenic mutations 
in Tau in frontotemporal dementia and parkinsonism linked to chromosome 17 
(FTDP-17), several groups described the formation of NFTs in neurons and 
glial cells in mice transgenic for mutant human tau. The first published NFT-
forming model expressed human P301L tau (Lewis et al., 2000). The P301L 
mouse model presents NFTs in brain and in spinal cord, also showed 
abnormal tau filaments. Moreover, the progression of neurofibrillary pathology 
and neuronal loss is also correlated with the progression of deficits in spatial 
memory, indicating a detrimental effect of NFTs on memory (Santa-cruz et al., 
2005). To reproduce the Aβ plaque and NFT pathologies in a single mouse 
model, double-transgenic strain was developed crossing Tg2576 mice that 
produce Aβ with JNPL3 tau mice (P301L mutation). This double transgenic 
mouse, called TAPP, showed amyloid pathology, that greatly enhanced NFT 
formation (Lewis et al, 2001).  
 
1.12.4 Multiple-transgenic models: Triple-Transgenic 
The 3xTg-AD mice, harboring mutations of APP (Swedish), PS-1 (M146V), 
and tau (P301L), has been developed by Oddo et al (2003b) to study the 
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interaction between Aβ and tau and their effect on synaptic function. 3xTg-AD 
mice gradually develop plaques and tangles. This is the first transgenic model 
to develop an age-related and neuropathological phenotype that includes both 
plaque and tangle pathology in AD relevant brain region. Synaptic dysfunction, 
including LTP deficits, appears in an age-related manner. Therefore, deficits in 
long-term synaptic plasticity correlate with the accumulation of intraneuronal 
Aβ (Oddo et al., 2003b). Interestingly, as is the case of human AD, it‟s find that 
Aβ deposits precede tau alterations in the 3xTg-AD mice. In subsequent 
studies, treatment of 3xTg mice with anti-Aβ antibodies, or antibodies specific 
for oligomeric forms of Aβ, led to the rapid clearance of accumulated Aβ 
deposition and early tau lesions in the cell body (Oddo et al, 2004; Oddo et al, 
2005). 
 
1.12.5 Tg2576 mouse model  
The APPSWE mouse was developed in the laboratory of Karen Hsiao at the 
University of Minnesota, in association with the Mayo Clinic. This model was 
created by microinjecting the human APP695 gene containing the double 
“Swedish” mutation (Lys670→Asn, Met671→Leu) K670N, M671L into 
B6SJLF2 zygotes (Hsiao et al, 1996). The mutant gene induced the 
overexpression of APP695 in the brains of mice over 2 months of age, and 
thus, elevated brain levels of Aβ (Hsiao et al, 1996). In addition to amyloid 
pathology, Tg2576 mice also show activated microglia, reactive astrocytes and 
neuritic dystrophy, which mimic what is observed in AD. Learning and memory 
abilities of these mice have also been measured using a large number of 
behavioural tests.  
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Chapter 2: Potassium channels 
2.1 Ion channels 
Ion channels are transmembrane proteins, inserted in the phospholipid bilayer 
of the plasma membrane (or organellar membranes) of cells, which passively 
consent the flow of ions in and out of the cell down their electrochemical 
gradient. Ion channels regulate ion flux in response to specific signalling 
stimuli that trigger the channels to switch between an “open” (in presence of 
the gating stimulus) and “closed” (in absence of the gating stimulus) 
conformational states. Ion channels can be divided into three classes that 
include slowly modulated channels, ligand-gated ion channels and voltage-
gated ion channels. Voltage-gated ion channels are essential for the 
production of action potentials which permit rapid transmission of signals 
between distant organs on a millisecond. These channels include sodium, 
calcium and potassium channels, as well as channels with mixed sodium-
potassium conductances and hyperpolarization-activated, cyclic-nucleotide 
gated, cation non-selective (HCN) channels. Sodium and calcium channels 
are composed of four concatemerized transmembrane domains each 
containing six transmembrane helices or segments, S1-S6. Instead, potassium 
channels exist as four separate subunits that are assembled together as 
tetramers (Xu et al., 1995). The three fundamental voltage-gated channel 
families work together to produce neuronal and myocyte action potentials. In 
addition to their physiological roles in maintaining cellular ion homeostasis and 
controlling the bioelectrical properties of the cell membrane, it has been shown 
that dysregulation of ion channel function has a role in many pathological 
diseases (channelopathies) (Kass et al., 2005). 
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2.2 Potassium channels 
Potassium (K+) channels include a large family of homologous membrane 
proteins. In excitable tissues, they regulate cardiac pacemaking, action 
potentials, and neurotransmitter release; in non-excitable cells, they play 
important roles in hormone secretion, cell proliferation, cell volume regulation, 
and lymphocyte activation, migration, differentiation, proliferation and 
apoptosis (Dubois et al., 1993; O'Grady et al., 2005). Potassium channels can 
be subdivided in different families, depending on the architecture of their 
conducting subunits (α subunit): two transmembrane domains and one pore 
channels (2TM/1P) (Yang et al. 1995); four transmembrane domains and two 
pore channels (4TM/2P) ; six transmembrane domains and one pore channels 
(6TM/1P) (Fig. 4). The 2TM channels are the phylogenetically oldest 
potassium channels; each subunit is composed of one pore region surrounded 
by two TM domains. Initially termed “anomalous” rectifiers, these channels 
conduct an inward potassium current and little outward current during 
depolarization. The 4TM channels, or tandem pore domain channels, are a 
class of potassium channels where each alpha subunit contains two pore-
forming sequences (Kim, 2005). Often termed leak or background channels, 
these channels are generally voltage-independent and can contribute to 
setting the resting membrane potential and regulating cellular excitability. 
Members of the 4TM channel group can be regulated endogenously by a 
variety of stimuli including pH, second messengers, temperature and also 
exogenously by general anesthetics. The 6TM channels are the largest class 
of potassium channels and are divided into two subclasses, the calcium-
activated and the voltage-gated channels. These channels are tetramers of 
6TM alpha subunits containing one pore domain each (Jenkinson, 2006). 
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Changes in voltage or intracellular calcium cause these channels to open and 
conduct an outward flow of potassium. Calcium-activated potassium channels 
include large (big), intermediate and small conductance channels (BK, IK and 
SK, respectively). The function of IK channels, expressed in erythrocytes and 
endothelium, includes the regulation of cell volume and blood pressure. SK 
channels are predominantly expressed in the nervous system and contribute 
to the after hyperpolarization that regulates action potential firing rates 
(Stocker, 2004). BK channels are highly expressed in smooth muscle and 
neurons and are involved in processes such as vasodilation and 
neurotransmitter release. 
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Fig.4 K
+
 channels architecture. 2TM/P channels consist of two transmembrane (TM) 
helices with a P loop between them and one pore region. 4TM/2P consist of two repeats of 
2TM/P channels. 6TM/1P channels consist of six transmembrane helices and one pore 
region. 8TM/2P channels are hybrids of 6TM/P and 2TM/P. S4 is marked with plus signs to 
indicate its role in voltage sensing in the voltage-gated K
+
 channels. 
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2.3 Voltage gated potassium channels 
Potassium channels activated by voltage are named voltage-gated potassium 
channels; nomenclature for these channels is “KV”, which represents the 
specificity for the potassium ion (K) and the mode of activation, voltage (v). 
According to the International Union of Pharmacology (IUPHAR) they are 
divided into twelve families, KV1-12. Phylogenetic trees of the KV channels 
divided these channels into three groups: a) KV1–KV6 and KV8–KV9 families; 
b) the KV7 family; c) the KV10–KV12 families (Gutman et al., 2003). The typical 
voltage-gated K+ channel assembles in four identical (or similar) 
transmembrane subunits surrounding a central pore. Each subunit has six 
transmembrane segments (S1–S6), with both N- and C- termini on the 
intracellular side of the membrane. Assembly into a tetramer forms two 
domains: a voltage sensing domain (S1-S4) and pore domain (S5-S6).  
 
2.3.1 The pore domain and the voltage sensor 
The pore domain contains two regulatory modules: the selectivity filter and the 
intracellular channel gate (Long et al. 2007). KV channels are selectively 
permeable to potassium, this selectivity is reached through a sequence of 
aminoacids near the extracellular side of the ion conducting pathway (Thr-Val-
Gly-Tyr-Gly) (Doyle et al., 1998). This sequence is crucial for the selectively 
filter of the channel; in fact mutations in this sequence lead to a lack of K+ ion 
selectively (Heginbotham et al., 1994). The access of ion conducting pore is 
controlled by intracellular gate comprised of the S6 C-terminal end, which form 
a bundle crossing that obstructs the pore when the channel is closed. The 
voltage sensing domain is comprised of the S1-S4 helices of the α-subunits 
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and is responsible for detecting changes in membrane potential. S4 playing a 
major role, contains a positive charged aminoacids (Lys o Arg) repetitively 4 to 
8 times. This creates a positively charged surface along the S4 which senses 
the membrane potential. S1-S3 segments, plenty of negative charges, 
complete the voltage sensing domain and help to stabilize the positively 
charged S4 segment in the lipid bilayer (Long et al., 2005). Upon membrane 
depolarization, the positively charged S4 helices move out toward the cell 
exterior, resulting in a widening of the ion conduction entrance. Membrane 
repolarization causes the S4 helices to move back into the membrane, forcing 
the shift of the linker helix between the S4 and S5. This movement near the 
intracellular side of the cell compresses the gate and prevents the flux of ions. 
 
2.3.2 The gating 
There are three established mechanisms by which the voltage-gated K+ 
channels can close: two of them involve a conformational constriction of the 
permeation pathway, and one involves conditional plugging of the pore by an 
auto-inhibitory part of the channel protein (Yellen, 2002).  
1) Sliding helix model: the channel can close by pinching shut at the 
intracellular entrance. This intracellular or S6 gate obstructs entrance from the 
cytoplasmic surface to the water-filled „cavity‟ in the centre of the channel 
protein (Durell et al., 1998). 
2) Transporter-like model: a second mechanism for closing the pore uses the 
S6 gate to regulate the binding of an auto-inhibitory peptide that is part of the 
channel. The N terminus of K+ channels can act as a channel blocker, 
probably by binding directly to the cavity (Chanda et al.,2005).  
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3) Paddle model in which a voltage sensor paddle comprised by S4 and the C-
terminal half of S3 form a rigid structure that moves through the membrane in 
a close proximity to S1 and S2 (Ruta et al, 2005). 
 
2.4 Traffic of KV channels 
KV channels are synthetized and assembled as tetrameric complexes in 
endoplasmic reticulum (ER) (Lu et al., 2001). The perfect folding of KV may 
require the intervention of chaperons such as Heat Shock Protein (Hsp) or 
calnexin. From the ER, KV channels complexes continue their journey to the 
plasma membrane, passing through cis-medial- and trans-Golgi elements. 
Along this trafficking to Golgi apparatus, KV channels undergo modification, 
such as N-linked glycosylation, tyrosine, serine or threonine‟s phosphorylation. 
Interestingly, phosphorylation modify channel‟s activity, surface membrane 
targeting and recycling (Misonou et al., 2004). Ubiquitination also regulates 
KV‟s membrane levels. 
 
2.5 Regulatory subunits 
Accessory subunits influence a wide range of KV channel properties, such as 
gating, post-translational modifications, traffic, subcellular localization and 
pharmacology. Different regulatory subunits have been described, some of 
them are cytoplasmic [KVβ subunits, KChip (K
+ Channel Interacting Proteins)] 
and KChAP (K+ Channel Associated Protein) and others are transmembrane 
proteins [(KCNEs and DPPLs (dipeptydil aminopeptidase like proteins)] (Li et 
al., 2006). KVβ are cytoplasmic regulatory subunits which interact with KV 
channels. There are three subfamilies of KVβ: KVβ1, KVβ2 and KVβ3. 
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Stoichiometry association with KV channels is 1:1 (Long et al., 2005). KVβ1 
interacts with all the member of KV1 members; KVβ2 interacts with KV1 and 
KV4 members; KVβ3 interacts with KV1.2, KV1.3, KV1.4 and KV1.5. KChips 
interact specifically with KV4 members, especially with KV4.2 and KV4.3. 
KChips slow the inactivation, regulate traffic and localization, modulate 
membrane mobility and endocytosis of KV4. Stoichiometry association with KV 
channels is 1:1. KChAP accessory subunits improve the current amplitude of 
KV channels and have a role as chaperone leading to an increase in the 
surface expression of the channel (Pourrier et al., 2003; Li et al., 2006). They 
can associate to KV1.1-1.5 and KV2.1-2.2. DPPLs interact with KV4 channels 
and lead to an increase in surface expression and a significant acceleration of 
the inactivation time of channels (Strop et al., 2004). KCNEs are small 
transmembrane proteins which interact with a wide range of KV channels. The 
family is composed of five members (KCNE1-5) and has an ubiquitous 
expression (McCrossan and Abbott, 2004). 
 
2.5.1 KCNE family 
KCNE genes encode a family of single transmembrane domain proteins called 
MinK-related peptides (MiRPs) that function as ancillary or β subunits of KV 
channels. MiRPs cannot form functional ion channels alone, however when 
co-expressed with pore forming KV α subunits, they form stable complexes 
and serve to modulate important biophysical properties of the channel. When 
co-expressed in heterologous systems, MiRPs confer changes in KV channel 
conductance, gating kinetics and pharmacology, and are fundamental to the 
properties of some native currents. The KCNE1 gene encoding MinK (Minimal 
K+ currents) was originally cloned from rat kidney in 1988 (Takumi et al., 
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1988). The name MinK reflects early thinking that this protein was the minimal 
size needed to form K+ channels. MinK is a 130-amino-acid protein with a 
molecular weight of 15 kDa. Two splicing isoforms have been described: 
KCNE1a, which is more ubiquitously; KCNE1b which is a heart specific 
isoform. The KCNE2 gene encoding minK-related peptide 1 (MiRP1),  
whereas KCNE3 and KCNE4 gene encoding MiRP2 and MiRP3 respectively. 
Human MinK and related peptides are integral membrane proteins, 103–177 
residues in length, their single transmembrane domain flanked by an 
extracellular N-terminal and cytosolic C-terminal. MiRPs cannot form 
functional ion channels alone, however they form stable complexes with pore 
forming KVα subunits. MiRP subunits may modulate the gating of a particular α 
subunit type. MinK/MiRPs are widely expressed in mammalian tissues, in 
particular into heart, smooth muscle and epithelia, skeletal muscle, and brain 
(Abbott et al., 2001; McCrossan et al., 2003; McCrossan and Abbott, 2004).  
 
2.6 KV3 channels 
The family of mammalian KV3 genes, related to the Drosophila Shaw gene, 
consisting of four subfamilies, encodes the subunits of tetrameric voltage-
gated K+ channels. There is convincing evidence that subunits of the same 
subfamily, but not of different subfamilies, form heteromultimeric channels. 
There are four KV3 genes known both in rodents and humans, that generate 
multiple products by alternative splicing. The analysis of cDNAs predicts the 
existence of twelve different Kv3 proteins in mammals. The four KV3 subunits 
are designated KV3.1-4 and encoded by the genes Kcnc1-4 in rodents or 
KCNC1-4 in humans. Kcnc1 has at least two known variants that change the 
C terminus of the protein designated KV3.1a and KV3.1b. Kcnc2 has three 
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variants and Kcnc4 has four known variants. Kcnc3 has three published and 
more unpublished variants affecting the 3‟UTR (Rudy et al., 1992; Rudy et al., 
1999). In rodents, three of the four KV3 genes (KV3.1−KV3.3) are expressed 
mainly in brain. KV3.4 is lowly expressed in brain, but strongly in skeletal 
muscle. Low levels of KV3.1 are also seen in skeletal muscle, while low levels 
of KV3.3 mRNAs are found in kidney and lung. KV3.1, KV3.3, and KV3.4 
products have also been identified in pheochromocytoma cells (PC12). Three 
of four KV3 genes (KV3.1, KV3.2, and KV3.3) are expressed largely in the CNS; 
whereas KV3.4 transcripts are also present in the CNS but are more abundant 
in skeletal muscle. In situ hybridization studies in the CNS reveal discrete and 
specific neuronal populations that express KV3 mRNAs. In the cerebral cortex, 
hippocampus, and caudate-putamen, subsets of neurons can be distinguished 
by the expression of specific KV3. KV3 mRNAs are distributed in a non-
homogeneous fashion throughout the CNS. In fact, some neuronal types 
exhibit undetectable labeling, suggesting that they do not express significant 
amounts of any KV3 mRNAs. Interestingly, many neuronal populations 
expressing KV3.1 transcripts also express KV3.3 mRNAs. Furthermore, KV3.4 
transcripts are present, although at lower levels, in several neuronal 
populations that also express KV3.1 and/or KV3.3 mRNAs, revealing a high 
potential for heteromultimer formation. Most neurons in the cerebral cortex, the 
epithalamus, and the hypothalamus, the amygdala, the substantia nigra 
compacta, and a few structures in the brainstem such showed undetectable 
labeling with KV3 probes. Others, such as the pyramidal neurons in the 
hippocampus, particularly in the CA1 were only weakly labeled. KV3 gene 
expression is prominent in the thalamus, cerebellum, brainstem, and spinal 
cord (Weiser et al., 1994). In the cortex and the hippocampus some KV3 
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mRNAs appear to be expressed in distinct sets of interneurons. Since KV3.4 
transcripts appear to be much less abundant throughout the CNS than the 
products of the three other KV3 genes, and are mainly expressed in neurons 
also expressing KV3.1 or KV3.3 mRNAs, KV3.4 subunits may act in CNS 
neurons as modulators of the inactivation properties of channels composed 
mainly of KV3.1 and KV3.3 proteins. The electrophysiological studies 
suggested that small amounts of KV3.4 transcripts might be sufficient to impart 
fast inactivating properties to channels composed mainly of the other KV3 
subunits. KV3 currents have several unusual properties that distinguish them 
from those of other K+ channels known. These include their activation voltage 
range that is more positive than that of other voltage-gated K+ channels. 
Another unusual feature of KV3 currents is their fast rate of deactivation upon 
repolarization, first described for KV3.1 currents expressed by Grissmer et al. 
These authors found that KV3.1 currents deactivated about 10 times faster 
than other voltage-gated K+ channels known at the time (Grissmer et al., 
1994). 
 
2.7 Regulation of KV3 channels 
Several sites for protein-kinase phosphorylation are found in regions of KV3 
proteins that are thought to be intracellular. Some of these sites are found in 
proteins encoded by all of the genes, some are found only in proteins encoded 
by a single gene, and some are specific to alternatively-spliced isoforms. 
Three kinase systems, cAMP-dependent protein kinase (PKA), protein kinase 
C (PKC), and cGMP-dependent protein kinase (PKG) have now been shown 
to modulate KV3 channels function in heterologous expression systems. KV3.1 
is modulated negatively by PKC (Macica et al., 2003). An exception is KV3.3, 
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the current of which is facilitated by PKC (Desai et al., 2008). PKA also 
modulates KV3 channels (Moreno et al., 1995). The channels are in addition 
sensitive to oxidative stress (Rudy et al., 1992). Less acute modulation also is 
exerted through association with auxiliary subunits (McCrossan et al., 2003). 
 
2.8 Pharmacology of KV3 channels 
The classic blocker for KV3 channels has been tetraethylammonium (TEA), 
which blocks ~90% of KV3 current at 1 mM where it has weak effects on 
calcium-activated potassium channels. KV3 channels are also very sensitive to 
4-aminopyridine (4-AP). A new set of peptides obtained from the venom of the 
sea anemone Anemonia sulcata, known as blood-depressing substance I and 
II (BDS-I and BDS-II) showed to block specifically, reversibly, and at low 
concentrations (IC50 values in the low nanomolar range) KV3.4 channels. 
These toxins, are 43 amino-acids long and differ at only two positions. They 
share no sequence homologies with other K+ channel toxins from sea 
anemones. Instead, it has been demonstrated  that BDS-I and BDS-II have 
some sequence homologies with other sea anemone Na+ channels toxins 
(Diochot et al., 1998). 
 
2.9 Contributions of Kv3 Channels to Neuronal Excitability 
Potassium channels are crucial regulators of neuronal excitability, setting 
resting membrane potentials and firing thresholds, repolarizing action 
potentials and limiting excitability. KV channels can be categorized based on 
their voltage sensitivity (low- or high-voltage activated) and inactivation 
tendencies [delayed rectifier (IK) or A-type (IA)] (Dodson and Forsythe, 2004). 
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Products of the KV3.1 and KV3.2 genes express similar delayed-rectifier type 
currents, while KV3.3 and KV3.4 proteins express A-type currents. A 
myelinated axon can be divided in three portions: an initial segment, where 
somatic inputs summate and initiate an action potential; a variable-length 
myelinated axon, which must reliably transmits the information as trains of 
action potentials; and a final segment, beyond which the synaptic terminal 
expands. Low-voltage-activated K+ channels are prevalent in the initial axonal 
segment and terminal segment, in addition to juxtaparanodal location at nodes 
of Ranvier. High-voltage-activated K+ channels are localized to 
somatodendritic regions, sometimes as density gradients. They are also 
localized on synaptic terminals and nodes of Ranvier in some CNS myelinated 
fibres (although not at peripheral nodes). Inactivating A-type channels are 
broadly expressed, contributing to activity-dependent effects on neuronal 
firing. They can also be localized to synaptic terminals. All KV3 currents 
activate relatively fast at voltages more positive than −10 mV, and deactivate 
very fast. The activation voltage and fast deactivation rates are believed to 
help these channels to fast repolarize action potentials without affecting the 
threshold for action potential generation. The fast deactivating current 
generates a quickly recovering after hyperpolarization, thus maximizing the 
rate of recovery of Na+ channel inactivation without contributing to an increase 
in the duration of the refractory period. These properties contribute to the 
ability of neurons to fire at high frequencies and to regulate the synaptic 
transmission. KV3 currents have several properties that differentiate them from 
other K+ channels. These include their activation voltage range that is more 
positive than that of other voltage-gated K+ channels. The channels with the 
nearest activation voltage (KV2.1 and KV2.2) show significant activation at 
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10−20 mV more negative potentials. Although Kv3 channel opening becomes 
significant at high potentials (more positive than −10 mV), the probability of 
channel opening increases with voltage and >80% of the channels are opened 
between +30 and +40 mV. 
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Chapter 3: Pathological implications of KV3 potassium 
channels 
 
3.1 Potassium dysregulation in Alzheimer‟s Disease 
A growing evidence demonstrated that Aβ peptide increases intracellular Ca2+ 
concentrations ([Ca2+]i) and disrupts Ca2+ homeostasis by several 
mechanisms, including modulation of voltage-gated Ca2+ channels, formation 
of Ca2+-permeable pores and inhibition of the Na+/Ca2+ exchanger (Wu et al. 
1997). Alteration of K+ channel function in brain cells appears to be relevant to 
AD pathophysiology. Treatment with neurotoxic Aβ fragments enhanced KV 
channel activity in mouse SN-56 hybrid septal neuroblastoma cells (Colom et 
al., 1998) and in primary rat cerebellar granule cells (Ramsden et al. 2001), as 
well as in rat cortical astrocytes (Jalonen et al., 1997) and microglial cells 
(Chung et al. 2001). Interestingly, the inhibition of K+ efflux, either by use of 
pharmacological tools or by increasing the extracellular K+ concentration, fully 
prevented cell death induced by Aβ (Colom et al., 1998). Taken together, 
these studies, which complement earlier observations on K+ channels 
expressed in fibroblasts, platelets and, possibly, neuronal tissues from 
patients with AD, appear to lend support the systemic K+-dysregulation 
hypothesis for AD (Etcheberrigaray and Bhagavan 1999). Pannaccione et al., 
in 2005, showed that the neurotoxic Aβ25-35 and Aβ1-42 peptides caused a 
dose-dependent and time-dependent enhancement of total outward K+ in 
NGF-differentiated PC-12 cells and primary rat hippocampal neurons. 
Biophysical and pharmacological dissection of the K+ conductances underlying 
total outward K+ currents in these cells showed that both fast inactivating (IA) 
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and non inactivating (IDR) components were enhanced by neurotoxic Aβ 
treatment. 
 
3.1.1 KV3.4 and Alzheimer‟s Disease 
Angulo et al. performed genomic analyses using cDNA arrays containing a 
pool of cDNAs. The authors focused the attention on genes whose expression 
changes in early stages of the disease, in order to find potential therapeutic 
targets useful in preventing the progression of the clinical symptoms. We 
found, for the first time, that the potassium channel KV3.4 is already up-
regulated in the early stages of AD. Moreover, the gene encoding KV3.4 was 
also overexpressed in the late stages of AD. Immunoblot analysis of KV3.4 in 
extracts from control and AD frontal cortex revealed a band at 105 kDa, 
corresponding to the molecular weight of the channel. The level of KV3.4 
channel protein in samples from AD early and samples from AD late was 
significantly higher than in controls. This result indicates that the increased 
level of expression of mRNA in AD samples correlates with higher levels of 
protein. KV3.4 immunoreactivity increased in AD only in association with 
amyloid deposits in senile plaques. Increased KV3.4 immunoreactivity 
occurred in the form of fine granular precipitates or larger granules 
surrounding βA deposits (Angulo et al., 2004). Pannaccione et al., in 2007, 
demonstrated that Aβ1–42 treatment induced a selective up-regulation of KV3.4 
channel subunits through the activation of the transcriptional factor NF-B. 
The action of Aβ1–42 was not limited only to the α subunit of KV3.4; in-fact, it 
also induced an over expression of MiRP2, a neuronal β-subunit co-
assembling with KV3.4 subunit and playing a crucial role in the control of its 
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biophysical properties and pharmacological profile (Abbott et al., 2001). The 
hypothesis that KV3.4 channels are involved in the Aβ1–42 neurotoxic effect was 
further supported by the results showing that BDS-I, a KV3.4 blocker (Diochot 
et al., 1998), exerted a potent neuroprotective action in hippocampal neurons 
and NGF-differentiated PC-12 cells exposed to Aβ1–42 peptide. 
 
3.2 Critical role of potassium homeostasis in apoptosis 
Apoptotic cells display a significant cell shrinkage, and K+ efflux has been 
suggested to mediate this loss of volume. Intracellular potassium 
concentrations ([K+]i) play a key role in cell survival. Cytoplasmic K+ loss has 
been shown to favor the activation of caspases and nucleases, which lead to 
apoptosis (Hughes et al., 1997; Cain et al., 2001). Indeed, several studies 
demonstrated that cellular K+ depletion by valinomycin (K+ ionophore) or 
plasma membrane K+ channel over-expression induces apoptosis in different 
cell types. Moreover, high extracellular K+ has been reported to inhibit both the 
extrinsic and the intrinsic apoptosis, probably by inhibiting the Cyt C release. 
Given that K+ efflux has been proposed to be a pro-apoptotic factor, plasma 
membrane potassium channels mediating K+ efflux out of the cell represent 
good candidates for apoptosis regulation. Furthermore, it has been 
demonstrated that serum deprivation or staurosporine induced apoptosis of 
cortical neurons in 24–48 hours. This event was associated with an early 
enhancement of IK current and loss of cellular K
+ (Yu et al., 1997). Attenuating 
the outward K+ current with TEA or elevated extracellular K+ reduced 
apoptosis (Yu et al., 1997).  
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3.2.1 KV3.4 and apoptosis 
A similar IK enhancement was verified with other apoptotic insults such as βA 
peptides (Yu et al., 1998). Exposure to Aβ fragment 25-35 or 1-42 enhanced the 
delayed rectifier K+ current IK, shifting its activation voltage relationship toward 
hyperpolarized levels and increasing maximal conductance. Reducing IK by 
adding TEA raising extracellular K+ to 25 mM attenuated Aβ-induced neuronal 
death (Yu et al., 1998). Furthermore, a study performed on SN56 cells, a 
cholinergic cell line from rat, described that treatment with Aβ1-42 increased 
delayed rectifier K+ currents and amplified cell death (Colom et al., 1998). As 
previously described, Pannaccione et al. have been demonstrated that Aβ1-42 
peptide induced a selective up-regulation of KV3.4 channel subunits through the 
activation of the transcriptional factor NF-B. In addition, this transcriptional 
event is associated with a current increase carried by this channel. In addition, 
hippocampal neurons and NGF-differentiated PC-12 cells over expressing 
KV3.4 showed an apoptotic nuclear process, as revealed by caspase-3 
activation and by Hoechst 33258-monitored abnormal nuclear morphology, thus 
suggesting a possible link between the enhanced expression and function of 
this K+ channel and the neurotoxic consequences provoked by Aβ exposure. 
The hypothesis that KV3.4 channels are involved in the Aβ1–42 neurotoxic effect 
was supported by the results showing that BDS-I, a KV3.4 blocker (Diochot et 
al., 1998), exerted a potent neuroprotective action in hippocampal neurons and 
NGF-differentiated PC-12 cells exposed to Aβ1–42 peptide (Pannaccione et al., 
2007). The relationship between KV3.4 and apoptotic cell death is demonstrated 
by the fact that the blockade of this channel was able to prevent the apoptotic 
process triggered by Aβ1–42 fragment.  
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3.3 Critical role of potassium homeostasis in memory and 
learning 
Advancing age is accompanied by deficits in learning and memory. Normal 
aging is associated with cellular and molecular changes which include a 
decrease in neuronal excitability and an alteration in synaptic plasticity. The 
age-related changes in neuronal function, as well as neuronal dysfunction 
associated with AD, may be the result of a dysregulation of the Ca2+ 
homeostasis. Many studies demonstrated the increase of intracellular Ca2+ in 
hippocampal neurons from aged animals or AD animal models. The increase in 
intracellular Ca2+ concentration has a number of functional consequences, the 
most relevant is a decrease in postsynaptic neuronal excitability. It‟s important 
to highlight that neuronal excitability affects plasticity and learning. This 
reduction in neuronal excitability could in turn lead an increase in the threshold 
for LTP, thus altering the ability of the hippocampus to encode information 
(Murphy et al., 2004). Emerging evidence indicates that KV channels are key 
regulators of neuronal excitability and that they have a critical role in learning 
and memory. (Giese et al. 2001; Solntseva et al. 2003). Primarily KV channels 
have a role in the setting of the resting membrane potentials and in the 
repolarization during actions potentials in excitable cells. KV channels are 
categorized based on their voltage sensitivity (low or high voltage-activated) 
and inactivation tendencies (delayed rectifier (IK) or A-type (IA) (Dodson and 
Forsythe, 2004). Collectively, KV channels set and stabilize resting membrane 
potential, repolarize action potentials (APs), and control the discharge 
frequency by regulating inter-spike intervals, thus they play a crucial role in the 
generation of neuronal electrical activity and influencing neuronal excitability. 
Changes of KV channel activity could lead to neuronal dysfunction and disrupt 
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cognition. As the number and pattern of APs are necessary to encode 
information (Reike et al., 1997), KV channel dysfunction may alter information 
processing and therefore be an important link in memory disturbances. 
Experiments in several model have shown that the reduction in K+ currents 
correlates with improved memory and LTP, whereas the increase in K+ currents 
corresponds to learning and memory deficiencies (Ghelardini et al. 1998; Alkon, 
1999). Importantly, increased KV4 currents lowers LTP induction probability 
(Watanabe et al., 2002), while decreased KV4 currents enhances LTP (Frick et 
al., 2004) and improves learning and memory (Lilliehook et al., 2003). Moreover 
KV2.1 channels regulate neuronal excitability during high frequency stimulation 
(Murakoshi and Trimmer, 1999; Du et al., 2000; Pal et al., 2003). 
Dephosphorylation of KV2.1 channels shifts their activation curves to more 
hyperpolarized potentials and increases their open channel probability 
(Murakoshi et al., 1997). The increased delayed rectifier current (IK) leads to a 
diminished LTP, which is reversible by re-phosphorylation, demonstrating a 
strong link to this potassium channel activity (Misonou et al. 2004). 
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Chapter 4: Aims and Design of the Present Study 
4.1 Rationale and aims of the present study 
Accumulating evidence suggests that KV3.4 play a role in AD pathogenesis. 
Thus, the goal of this study was to further the knowledge about the function 
played by KV3.4 in a transgenic mouse model of Alzheimer‟s disease, Tg2576. 
In particular, the specific objectives of the PhD thesis were: 
1. the evaluation of KV3.4 and MiRP2 protein expression in the hippocampus of 
Tg2576 and age-matched WT mice; 
2. the assessment of KV3.4 activity by patch clamp experiments in Tg2576 and 
WT hippocampal neurons; 
3. to evaluate the implications of KV3.4 in different stages of AD; 
4. to assess if the pharmacological or transcriptional modulation of KV3.4 could 
affect AD progression.  
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Chapter 5: Materials And Methods 
5.1 Drugs And Chemicals 
Poly(D)-lysine Hydrobromide Mol Wt 30,000-70,000 (P7280), Poly(D)-lysine 
Hydrobromide Mol Wt >300,000 (P7405), Poly-L-lysine hydrochloride (P2658), 
Cytosine β-D-arabinofuranoside (Ara-C), Nimodipine, Bovine Serum Albumin 
(BSA), Deoxyribonuclease I from bovine pancreas (DNAse), Trypsin from 
bovine pancreas, Proteinase K from Tritirachium album, TRI Reagent Solution,  
mouse monoclonal anti-α-Tubulin, rabbit polyclonal anti-GFAP, mouse 
monoclonal anti-Aβ (1-17) antibody (4G8) as well as all other materials for 
solution preparation, were from Sigma Aldrich (Milan, Italy). BDS-1, nerve 
growth factor (NGF 2.5S), Tetrodotoxin (TTX), rabbit polyclonal anti-KV3.4, 
rabbit polyclonal anti-MiRP2, were from Alomone Labs (Jerusalem, Israel). 
Roswell Park Memorial Institute (RPMI) 1640 Medium, Dulbecco's Modified 
Eagle Medium (DMEM), Hanks' Balanced Salt Solution (HBSS), Minimum 
Essential Medium (MEM), Opti-MEM I Reduced Serum Medium, Horse Serum 
(HS), Fetal Bovine Serum (FBS), L-glutamine, Penicillin-Streptomycin, Trypsin-
EDTA (0.05%), Phosphate-Buffered Saline (PBS), Lipofectamine 2000, 
Lipofectamine 3000 were purchased from Thermo Fischer (Massachusetts, 
USA), Invitrogen (California, USA). Rabbit polyclonal anti-caspase 3, rabbit 
polyclonal anti-caspase 6, rabbit monoclonal anti-Aβ (17-42) antibody were 
purchased from Cell Signaling (Massachusetts, USA). Rabbit polyclonal anti-
APP antibody was purchased from Ab-cam (Cambridge, UK). 
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5.2. Mice 
Animals were kept under standard conditions of temperature, humidity and light, 
and were supplied with standard food and water ad libitum. Animals were 
handled in accordance with the recommendations of International Guidelines for 
Animal Research and the experimental protocol was approved by the Animal 
Care and Use Committee of “Federico II” University of Naples. All efforts were 
made to minimize animal suffering and to reduce the number of animal used. 
Heterozygous male Tg2576 mice and wild-type (WT) littermates, obtained 
backcrossing male Tg2576 mice with F1 WT female, were used for all 
experiments. Tg2576 mice, purchased from commercial source [B6;SJL-
Tg(APPSWE)2576Kha, model 1349, Taconic, Hudson, NY], are well-
established AD-related mouse model carrying the human APP Swedish 
670/671 mutation (K670N e M671L; Hsiao et al., 1996). F1 wild-type female 
(B6;SJL) littermates were obtained crossing female C57BL/6 with male SJL; 
C57BL/6 and SJL mice were purchased from Charles River. 
 
5.2.2 Genotyping: PCR Analysis 
Genomic DNA from mouse tails was isolated with salt precipitation method. 
Tails after the cut were incubated with tail digestion buffer (50 mM Tris-HCl pH 
8.0, 100 mM EDTA pH 8.0, 100 mM NaCl, 1% SDS) supplemented with 
Proteinase K (Sigma Aldrich, Milan, Italy) at a final concentration of 0.5 mg/ml 
and placed in water bath at 55-60°C overnight with mixing. This step should 
result in the complete solubilization of the tail fragment. Embryonic brain tissue 
was kept during cerebral dissection and frozen immediately upon collection. 
After thawing, we added TRI Reagent to each sample in order to homogenize 
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the tissue. Subsequently one volume of phenol:chloroform:isoamyl alcohol 
(25:24:1) was added to each sample. After centrifugation, the mixture separated 
into 3 phases: an aqueous phase containing the RNA, the interphase containing 
DNA, and an organic phase containing proteins. We discarded and collected 
the interphase in a new centrifuge tube for each sample. After we proceeded to 
DNA precipitation with 100% ethanol; we centrifuged the sample at 4°C for 30 
minutes at 16,000 × g to pellet the DNA. Carefully we remove the supernatant 
without disturbing the DNA pellet; after we added 70% ethanol and centrifuged 
each sample at 4°C for 2 minutes at 16,000 × g. We removed as much of the 
remaining ethanol as possible and we dried the DNA pellet at room temperature 
for 5–10 minutes. Finally we resuspended the DNA pellet in TE buffer (Tris-
EDTA) by pipetting up and down 30–40 times .DNA concentration and purity of 
each sample was quantified using Nanodrop Spectrophotometer (Thermo 
Fisher Scientific, Wilmington, DE,US). We used following primers to amplify the 
DNA region with human APP Swedish mutation on both types of genomic DNA: 
5′-CTGACCACTCGACCAGGTTCTGGGT-3′ and 5′GTGGATAACCCCTCCCCC 
AGCCTAGACCA-3′ (Primm, Milan, Italy). 50 ng/µL of DNA were used for PCR 
reaction. The amplification protocol (30 cycles) was the following: 95°C for 45 s, 
55°C for 60 s, 72°C for 60 s. Each 25-µL reaction contained: 1U of AmpliTaq 
DNA Polymerase (Lucigen, US) and 0.5 µM of each primer. The amplification 
products were visualized on agarose (2%) gel by loading approximately half (10 
µL) of each reaction per lane. The band of 466bp indicated the transgenic 
genotype, whereas its absence indicated the wild type genotype. 
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5.2.3 Behavioural tests 
AD is characterized by progressive decline in episodic memory and in cognitive 
abilities. Thus, a valid AD-transgenic model must reflect the behavioral changes 
observed in AD patients.  
 
5.2.3.1 Open Field 
The open field locomotion test is used primarily to examine motor function 
measuring spontaneous activity in an open field. It is also used to assess 
anxiety and exploration ability (in particular time spent in the center of the field). 
The circular or square open fields vary in size and are divided into distinct 
quadrants or sections. The animal is positioned in the open field and their 
movements are videotaped or monitored. We placed each mouse in the center 
of a chamber; mice are allowed to freely explore the chamber for the duration of 
the test session (5-minutes). Rodents typically spend a significantly greater 
amount of time exploring the periphery of the arena, usually in contact with the 
walls, than the center area. Mice that spend significantly more time exploring 
the unprotected center area demonstrate anxious behavior. Many software 
systems allow the researcher to designate center area, as well as multiple other 
regions of the test chamber, to track exploratory activity. The most commonly 
used measure to evaluate exploratory/locomotor activity is the total distance 
traveled.  
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5.2.3.2 T maze spontaneous alternation 
The most extensively used paradigms for working memory in mice are maze 
(labyrinth) type tasks which require spatial working memory to solve. T-maze 
tasks are extensively used for cognitive behavioral testing in both mice and rats. 
These tasks are based on the natural exploratory behavior of rodents, in 
particular about the tendency to choose an alternative/new arm rather than 
familiar arm which has been previously explored. The T-maze is an apparatus 
in the form of a T placed horizontally. Animals are started from the base of the T 
and free to choose one of the goal arms. If two trials are given in quick 
succession, on the second trial the rodent tends to choose the arm not visited 
before, reflecting memory of the first choice. This is called “spontaneous 
alternation”. Spontaneous alternation is sensitive to dysfunction of the 
hippocampus, but other brain structures are also involved. Each trial should be 
completed in under 2 minutes, but the total number of trials required will vary (at 
least ten trials) (Deacon and Rawlins, 2006). 
 
5.3 Cell Cultures 
5.3.1  PC-12 Cells 
Rat pheochromocytoma cells (PC-12 cells), a clonal cell line derived from a 
pheochromocytoma of the rat adrenal medulla, were grown in 100 mm plastic 
Petri dishes in 85% RPMI 1640, 10% HS and 5% heat-inactivated fetal FBS, 
containing penicillin (5U/mL) and streptomycin (5μg/mL), at 37°C with 5% CO2. 
For electrophysiological experiments and morphological analysis, cells were 
seeded at low density on glass coverslips (Glaswarenfabrik Karl Hecht KG, 
Sondheim, Germany) coated with poly-L-lysine (50 µg/mL). Differentiation of 
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PC-12 cells was achieved by treatment with NGF 2.5S (50 ng/mL) for 7 days 
(Greene and Tischler 1976). In order to assess the differentiation status of the 
cells, in some experiments a “differentiation score” was calculated by means of 
phase contrast microscopy analysis (Eclipse E400 microscope; Nikon, 
Torrance, CA, USA). This was based on the number of neurites and the length 
of neuritic extension: 0, round cells; 1, cells with any extension of one or more 
neurite, each less than one body length; 2, extension of one or more neurites 
between one or two cell body lengths; and 3, at least one neurite of more than 
two body lengths in size (Pannaccione et al., 2007). Moreover the expression of 
the axonal growth associated protein 43 (GAP-43) and the synaptic protein 
synapsin I could be evaluated by Western blot during cell differentiation (Das et 
al., 2004). 
 
5.3.2 Chinese Hamster Ovary Cells (CHO) 
For our studies, we adopted as a heterologous expression system the Chinese 
Hamster Ovary Cells (CHO) cells. KV3.4 and Mirp2 cDNAs were expressed in 
CHO cells by transient transfection. CHO cells were grown in 100 mm plastic 
Petri dishes in DMEM containing 10% FBS, penicillin (5 U/ml), and streptomycin 
(5 µg/ml) at 37°C with 5% CO2. For electrophysiological experiments, cells were 
seeded on glass coverslips (Glaswarenfabrik Karl Hecht KG, Sondheim, 
Germany) coated with poly-L-lysine (50 µg/mL) and transfected the next day 
with the appropriate cDNAs using Lipofectamine 2000 (Invitrogen) according to 
guidelines for transfection. To dilute Lipotectamine 2000 it‟s recommended Opti-
MEM I Reduced Serum Medium in the absence of antibiotics. Total cDNA in the 
transfection mixture was kept constant at 4 μg: 2 μg of KV3.4 cDNA and 2 μg of 
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MiRP2 cDNA. We performed electrophysiological experiments usually 48 hours 
after transfection. 
 
5.3.3 Mouse Hippocampal Neurons 
Primary neuronal cultures were prepared from Tg2576 and WT hippocampi of 
embryonic day (E). Embryonic age (E) was calculated by considering E0.5 the 
day when a vaginal plug was detected. Briefly, pregnant animals were 
anesthetized and sacrificed by cervical dislocation. Hippocampal tissues from 
embryos were dissected in ice-cold dissecting medium (HBSS supplemented 
with 27 mM glucose, 20 mM sucrose, 4 mM sodium bicarbonate), centrifuged, 
and the resulting pellet was mechanically dissociated with a fire polished glass 
pipette. Cells were resuspended in plating medium consisting in Eagle‟s MEM 
(MEM, Earle‟s salts, supplied bicarbonate-free) supplemented with 5% FBS, 5% 
HS, 2 mM L-glutamine, 20 mM glucose, 26 mM bicarbonate, and plated on 
35mm culture dishes or onto 25 mm glass coverslips (Glaswarenfabrik Karl 
Hecht KG, Sondheim, Germany) coated with 100 μg/ml poly(D)-lysine at a 
density of one embryo hippocampi/1 ml. Three days after plating, non-neuronal 
cell growth was inhibited by adding 10μM of cytosine AraC. 24 hours after this 
treatment, the planting medium was replaced by growth medium (Eagle‟s 
Minimal Essential Medium with 20 mM glucose, 26 mM NaHCO3 supplemented 
with 2mM L-glutamine and 10% HS. Neurons were cultured at 37°C in a 
humidified 5% CO2 atmosphere. All the experiments were performed between 
8-16 days in vitro (DIV).  
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5.3.4 Primary Astrocyte Cultures 
Primary astrocyte cultures were obtained from 1-2-day-old rat pups. The animal 
was sacrificed by decapitation using the scissors. Their brains were then 
removed under aseptic conditions and placed in ice cold Ca2+/Mg2+-free HBSS. 
Under a stereomicroscope, total brains were stripped of meningeal tissues and 
cut into small fragments. After we placed dissected brain tissues in DMEM 
containing 0.05% trypsin and 0.003% DNase and kept at 37°C for 30 minutes. 
The tissue was then mechanically dissociated using a Pasteur pipette and 
centrifuged at 1000 rpm for 10 minutes. The pellet was resuspended in a 
solution of DMEM containing only 0.003% DNase and again mechanically 
dissociated with a Pasteur pipette. After another centrifugation (1000 rpm, 10 
minutes), the cells were resuspended in DMEM supplemented with 10% FBS, 
100 U/mL penicillin, 100 µg/mL streptomycin, and 2 mM L-glutamine and plated 
in flasks pre-coated with poly-L-lysine and cultured at 37°C in a 5% CO2 
incubator. The medium was changed 24 hours after plating and twice a week 
thereafter. Once became confluent, the cultures were shaken vigorously to 
remove non-adherent cells and subcultured 1:3. Upon becoming confluent 
again, the cells were then mechanically purified and subcultured again 1:4 
before performing the experiments. This protocol produced 98% of GFAP-
positive cells. For electrophysiological experiments and morphological analysis, 
astrocytes were seeded at low density on glass coverslips (Glaswarenfabrik 
Karl Hecht KG, Sondheim, Germany) coated with poly-L-lysine (50 µg/mL). 
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5.4 Solubilization of Aβ peptide and cellular treatments 
The peptide used in our study was produced by chemical synthesis from Sigma 
Aldrich (Milan, Italy) or INBIOS (Naples, Italy) using the Aβ1-42 sequence of 
human APP [UniProtKB-P05067 (A4_HUMAN)]. Both sources yielded peptide 
of 95% purity, assessed with high performance liquid chromatography (HPLC) 
and demonstrated the correct molecular mass by mass spectrometry analysis. 
Lyophilized peptide was stored in sealed glass vials in desiccated containers at 
-20 °C. Prior to resuspension, each vial was allowed to equilibrate to room 
temperature for 30 min to avoid condensation upon opening the vial. The first 
step in resuspending the lyophilized peptide was treatment in 1,1,1,3,3,3-
hexafluoro-2-propanol (HFIP; catalog number H8508; Sigma, Milan). Each vial 
of peptide was diluted in 100% HFIP to 1 mM. The clear solution containing the 
dissolved peptide was then aliquoted in microcentrifuge tubes and dried under 
vacuum in a SpeedVac until complete elimination of the solvent and recovery of 
the dried powder. Immediately prior to use, the HFIP-treated aliquots were 
carefully and completely resuspended to 5 mM in anhydrous dimethyl sulfoxide 
(Me2SO; catalog number D-2650; Sigma). 
 
5.4.1 Aβ1–42 Oligomers conditions 
Aβ1–42 oligomers were prepared by diluting 5 mM Aβ1–42 in Me2SO to 100 µM in 
ice-cold cell culture medium (phenol red-free Ham‟s F-12), immediately 
vortexing for 30 s, and incubating at 4 °C for 24 h. At the end of 24 h, the 
solution containing Aβ1–42 oligomers was centrifuged at 14000 rpm at 4° C for 
10 minutes. The supernatant, containing Aβ1–42 oligomers, was recovered and 
than aliquoted and stored at -20 °C (Stine et al., 2003). Before all experiments, 
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we tested a pre-aggregated preparation of the Aβ1–42. SDS-PAGE was 
performed using rabbit monoclonal anti-Aβ-antibody (Cell signaling, 
Massachusetts, USA ), which recognizes an epitope within residues 17-42 of 
human Aβ. Results showed that the oligomers between 12-15 kDa were the 
major species of Aβ1–42 peptide in the preparation. Aβ1-42 exposure was carried 
out in growth medium at the final concentration of 5 μM. When we performed 
time-course experiments, the Aβ1-42 was added to culture medium at above 
mentioned concentration for 24 or 48 hours and kept throughout the 
experiment. 
 
5.5 Electrophysiological recordings 
K+ currents were recorded, by patch-clamp technique in whole-cell 
configuration, in the following experimental groups: a) NGF-differentiated PC-
12; b) NGF-differentiated PC-12+KV3.4 and Mirp2 cDNAs; c) CHO; d) 
CHO+KV3.4 and Mirp2 cDNAs; e) WT hippocampal neurons; f) Tg2576 
hippocampal neurons; g) astrocytes; h) astrocytes+Aβ1-42. Currents were 
filtered at 5 kHz and digitized using a Digidata 1322A interface (Molecular 
Devices). Data were acquired and analyzed using the pClamp software (version 
9.0, Molecular Devices). All recordings were performed at room temperature 
(20-21°C). The pipette solution contained (in mM): 140 KCl, 2 MgCl2, 10 
HEPES, 10 glucose, 10 EGTA and 1 Mg-ATP, adjusted at pH 7.4 with KOH. 
The extracellular solution contained (in mM) 150 NaCl, 5.4 KCl, 3 CaCl2, 1 
MgCl2 and 10 HEPES, adjusted pH 7.4 with NaOH. All experiments with 
neurons and astrocytes as cellular model were performed in the presence of 
nimodipine (10 μM) to block L-type Ca2+-channels and TTX (50 nM) to block 
Na+-currents in the extracellular solution. To discriminate K+ current 
 68 
 
components with distinct inactivation properties (namely an inactivating 
component IA and a delayed rectifier non-inactivating component IDR), 
appropriate electrophysiological protocols were used. The total outward K+ 
current (IA + IDR) was measured by applying depolarizing voltage steps of 250 
ms duration from a holding potential of -80 mV to +40 mV, preceded by 
conditioning pulses at -100 mV lasting 1.5 s, which allowed full recovery from 
inactivation of IA. Following this protocol, IDR was isolated by stepping from -80 
to +40 mV for 250 ms, after conditioning pulses at -40 mV lasting 1.5 s to fully 
inactivate IA. The IA component was obtained by subtracting the isolated IDR 
component from the total K+ current. Current amplitudes were measured for IA 
and IDR at +40 mV, at the peak or at the end of the depolarizing pulse 
respectively. Steady-state properties of IA inactivation were measured by a 
voltage protocol in which a 125-ms depolarizing pulse to a constant voltage of 
+40 mV was preceded by 1.5-s conditioning pulses from -120 to +40 mV. 
Possible changes in cell size were taken into account by measuring, in each 
cell, the membrane capacitance, which is directly related to membrane surface 
area, and by expressing the current amplitude data as current densities 
[picoamperes/picofarads (pA/pF)]. Capacitive currents were elicited by 5-mV 
depolarizing pulses from -80 mV and acquired at a sampling rate of 50 kHz. The 
capacitance of the membrane was calculated according to the following 
equation: Cm= Cm∞ where Cm is membrane capacitance, C is the 
time constant of the membrane capacitance, Io is the maximum capacitance 
current value, m is the amplitude of the voltage step, and ∞ is the amplitude 
of the steady-state current.  
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5.6 Western Blotting 
To obtain total lysates for immunoblotting analysis, astrocytes, PC-12, CHO 
cells were washed in PBS and collected by gentle scraping in ice-cold RIPA 
buffer containing in mM: 50 Tris pH 7.4, 100 NaCl, 1 EGTA, 1 PMSF, 1 sodium 
orthovanadate, 1 NaF , 0.5% NP-40, and 0.2% SDS supplemented with 
protease inhibitor cocktail II (Roche Diagnostic, Monza, Italy). After sonication 
and incubation for 1 hour on ice, we centrifuged at 12,000 rpm at 4 °C for 30 
minutes and collected the supernatants. Mice brain tissues from Tg2576 and 
WT were homogenized in a glass teflon grinder (10 strokes at 500 rpm in about 
1 min) using a lysis buffer containing (in mM): 250 sucrose, 10 KCl, 1.5 MgCl2, 
1 EDTA, 1 EGTA, 1 dithiothreitol, 20 HEPES, pH 7.5, (Angulo et al. 2004) and 
completed with Protease Inhibitor Cocktail II (Roche Diagnostic, Monza, Italy). 
Tissue suspensions were then sonicated and incubated for 1 hour on ice. After 
centrifugation at 12,000 rpm at 4 C for 5 min, the supernatants were collected. 
The protein content of resulting supernatant was determined using the Bradford 
reagent. 70 μg of proteins were mixed with a Laemmli sample buffer; then, they 
are applied and resolved on SDS-PAGE polyacrylamide gels. Following transfer 
onto nitrocellulose membranes (Hybond-ECL, Amersham Bioscience, UK), non-
specific binding sites were blocked by incubation for 2 hrs at 4°C  with 5% non-
fat dry milk (Bio-Rad Laboratories, Milan, Italy) in TBS-T buffer; subsequently,  
incubated with primary antibodies overnight at 4°C. After three 10-min washes 
with TBS-T, the membranes were incubated 1h with the appropriate secondary 
antibody. Excessive antibodies were then washed away three times (10 min) 
with TBS-T. Immunoblots were visualized by enhanced chemiluminescence 
(ECL) (Amersham-Pharmacia-Biosciences, UK). Films were developed using a 
standard photographic procedure and the relative levels of immunoreactivity 
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were determined by densitometry using ImageJ Software (NIH, Bethesda, MA, 
USA). Primary antibodies used were: rabbit polyclonal anti-KV3.4 (1:1000 
Alomone Labs), rabbit polyclonal anti-GFAP (1:8000, Sigma Aldrich), 
monoclonal anti-human β-Amyloid (1-17) (1:1000, 4G8, Sigma Aldrich), 
polyclonal anti β-Amyloid (D54D2) XP rabbit mAb (1:1000 Cell Signaling), rabbit 
polyclonal anti-cleaved caspase-3 (1:1000, Cell Signaling), rabbit polyclonal 
Caspase-6 (1:1000, Cell Signaling), rabbit polyclonal anti-APP (Ab-cam) and 
mouse monoclonal anti-Tubulin (1:3000; Sigma Aldrich). Immunoreactive bands 
were detected using the chemiluminescence system (Amersham-Pharmacia-
Biosciences, UK). Proteins were visualized with peroxidase-conjugated 
secondary antibodies, using the enhanced chemiluminescence system 
(Amersham-Pharmacia Biosciences LTD, Uppsala, Sweden). The software 
Image J (NIH) was used for densitometric analysis..  
 
5.7  Immunoprecipitation  
Immunoprecipitation (IP) is the affinity purification of antigens using a specific 
antibody immobilized to a solid support (agarose beads). Immunoprecipitation is 
one methods to isolate proteins from cell or tissue lysates for the detection by 
Western Blot and other techniques. The first phase of IP was the preclearing, 
designed to remove potentially reactive, non-specific components from the 
lysate prior to the immunoprecipitation procedure. The approach to preclear the 
lysate was to incubate the sample with a nonspecific antibody or serum from the 
same host species as the IP antibody. Therefore agarose beads were used to 
remove nonspecific binding. We added 0,25 µg of irrelevant antibody of the 
same species and isotype as the IP antibody, or normal serum to 1 mL of the 
lysate with 20μL of agarose beads (Protein A-Agarose, Protein G-Agarose, 
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Protein A/G-Agarose or Protein L-Agarose); we incubated for 1 hour at 4° C. 
We centrifuged at 3000 rpm for 30 seconds, discarded beads pellet and kept 
supernatant for immunoprecipitation. In a new tube we added 100-1000 µg of 
the lysate plus the recommended amount of antibody. The amounts will be 
chosen depending on the abundance of the protein and the affinity of the 
antibody for the protein. We incubated the sample with the antibody 1-2 hours 
at 4°C under rotary agitation. Then we mixed 20 µL of the beads to each 
sample; beads will tend to stick to the sides of the tip so we try to minimize the 
movement in the pipette, thus it‟s recommended to use a tip cut 5mm from the 
top. We incubated the lysate-beads mixture at 4°C overnight under rotary 
agitation. When the incubation time is over, we centrifuged the tubes at 3000 
rpm for 30 seconds, we removed the supernatant and washed the beads in lysis 
buffer three times (each time centrifuging at 4°C and removing the supernatant). 
We removed the supernatant and added 40 µL of 2X loading buffer (Laemmli) 
and boiled at 95-100° C for 5 minutes to denature the protein and separated it 
from the beads. At the end we performed SDS-PAGE.  
 
5.8 Assessment of nuclear morphology  
Nuclear morphology in PC-12 and astrocytes was evaluated by staining the 
nucleus with the fluorescent DNA-binding dye Hoechst-33258 (Sigma, Milan, 
Italy). Astrocytes morphology was evaluated by cytoskeletal F-actin with 
rhodamine phalloidin (Sigma, Milan Italy). To this aim, PC-12 cells and 
astrocytes in the presence or in the absence of 5µM Aβ1-42 were fixed in 4% 
paraformaldehyde, washed in PBS and incubated for 20 min in PBS containing 
1 µg/ml Hoechst-33258 at 37°C. Astrocytes were incubated also with 
rhodamine phalloidin (1:200). Coverslips were mounted on glass slides and 
 72 
 
observed by fluorescence microscopy on a Nikon Eclipse E400 microscope 
(Nikon, Torrance, CA, USA). Digital images were taken with a CoolSnap 
camera (Media Cybernetics Inc., Silver Spring, MD, USA), and analyzed with 
the Image-Pro Plus 4.5 software (Media Cybernetics Inc., Silver Spring, MD, 
USA). Pathological nuclei were characterized by chromatin condensation 
(pyknosis), fragmentation, or by a decrease in size. The number of pathological 
nuclei of both PC-12 cells and astrocytes and the number of processes of 
astrocytes under control conditions and 48 hours after Aβ1-42 exposure were 
analyzed. 
 
5.9 Immunocytochemistry  
Cell cultures were fixed in 4% paraformaldehyde for 30 minutes at room 
temperature and then we washed the cells three times with PBS. The cells can 
be stored in 0.02% (w/v) sodiumazide in PBS at 4°C for several days or 
incubated immediately with primary antibody. After blocking in Bovine Serum 
Albumin (BSA) cells were incubated with primary antibodies for 24 or 48 hours. 
The primary antibodies used in these experiments were the following: rabbit 
polyclonal anti-KV3.4, mouse monoclonal anti-KV3.4 (Ab Nova, Taiwan), rabbit 
polyclonal anti-GFAP. Subsequently, they were incubated in a mixture of 
fluorescent-labeled secondary antibodies. Images were observed using a Zeiss 
LSM510 META/laser scanning confocal microscope. Single images were taken 
with an optical thickness of 0.7 µm and a resolution of 1024x1024. Nuclear 
morphology was evaluated by using the fluorescent DNA-binding dye Hoechst-
33258. All images were obtained with an x40 objective with identical laser 
power settings.  
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5.10 RNA interfering  
For transfection of cells with siRNA we used HiPerFect Transfection Reagent 
(QIAGEN). We tested two siRNA specific for rat KV3.4 genes named 
Rn_LOC684516_1 and Rn_LOC684516_2, in rat hippocampal neurons at 10nM 
and 20nM. After 48 hours we evaluated the silencing efficiency by Western Blot 
analysis. Moreover we tested three siRNA specific for mouse KV3.4 genes 
named Mm_Kcnc4_4, Mm_Kcnc4_5, Mm_Kcnc4_6, in mouse hippocampal 
neurons at 20nM. The ratio of HiPerFect Transfection Reagent to siRNA should 
be optimized to obtain higher silencing efficiency. We used a specific ratio: 5 nM 
siRNA and 3 µl HiPerFect Transfection Reagent. For our experiments we used 
AllStars Negative Control siRNA (QIAGEN) that provided minimal nonspecific 
effects on gene expression. Silencing of KV3.4 in WT and Tg2576 mice was 
performed through intracerebroventricular (i.c.v.) infusion of specific siRNA 
(Pignataro et al., 2011; Pignataro et al., 2012). In brief, anesthetized mice were 
first positioned on a stereotaxic frame, and then a 26-g stainless steel guide 
cannula (23 Gauge, Plastic One), connected to an osmotic pump (Alzet), was 
implanted into the right lateral ventricle using the following stereotaxic 
coordinates from bregma: AP -0.1mm caudal; LL –0,75mm lateral; 2,1 mm 
below the dura. Next, siRNAs, at a final concentration of 1 μM, were 
intracerebroventricularly (i.c.v.) infused every 24 hours for three consecutive 
days. Finally, at the end of 72 hours mice were sacrificed and brain samples 
collected for immunoblotting.  
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5.11 Statistical Analysis  
Statistical analysis were performed with ANOVA followed by Newman test or 
Student t-test. Differences were considered to be statistically significant at 
p<0.05. 
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  RESULTS 
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Chapter 6: Results 
 
6.1 Aβ1-42 peptide aggregates to form low molecular weight 
oligomers (dimers and trimers) in Tg2576 mice at the early 
stages of AD. 
 
The Tg2576 mouse model overexpresses a human APP transgene containing 
the Swedish FAD mutation (K670N/M671L) that causes the increase in βA 
levels. Furthermore, transgenic APP mice showed pathogenic βA aggregates 
that initiate a cascade of molecular events culminating in extensive 
neurodegeneration. In this study, principally, we investigated the events 
occurring in the early phase of AD. First we measured the deposition of βA 
aggregates, in particular β-amyloid trimers (βA1-42 trimers) in brain tissue 
obtained from Tg2576 mice compared to age-matched Wild-Type (WT) mice. 
Western Blot analysis showed a specific band of 15 kDa corresponding to βA1-
42 trimers only in Tg2576 brain tissue, whereas no band at 15 kDa was 
observed in age-matched Wild-Type (WT) mice (Fig. 5A). Furthermore we 
dissected Tg2576 and WT brain tissue in: cerebellum, cerebral cortex, 
striatum and hippocampus. In each area of Tg2576 mice we observed βA1-42 
trimers deposition. We evaluated also the APP protein expression in Tg2576 
and WT mice. We found a specific band of 100 kDa corresponding to APP 
both in WT and Tg2576 brain tissue. As expected, in Tg2576 brain tissue APP 
protein expression was significantly augmented (Fig. 5A). 
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6.2 Aβ1-42 trimers deposition in young Tg2576 mice correlates 
with the overexpression of KV3.4 Channel Subunits and its 
accessory subunit MiRP2 
 
Immunoblot analysis performed with a KV3.4 specific antibody on protein 
extracts from WT and Tg2576 hippocampal tissue revealed one band at 110 
kDa corresponding to native subunit monomer (McMahon et al., 2004), (Fig. 
5B). We analyzed the KV3.4 protein expression at different stages of AD 
pathology evolution; in particular we selected Tg2576 and age-matched WT 
mice at the early (3 months of age), middle (8 months of age) and late (12 
months of age) stages of AD (Braak and Braak, 1997). Densitometric analysis 
showed that the band at 110 kDa was significantly more intense in 
hippocampal tissue obtained from 3 months old Tg2576 mice compared to 
age-matched WT mice (Fig. 5C). Moreover, in the hippocampus of 8 months 
old Tg2576 mice we still observed a significant increase in KV3.4 protein 
expression compared to age-matched WT mice. Conversely, in the 
hippocampus of elderly Tg2576 mice (12 months of age) we observed a 
significant down regulation of KV3.4 protein expression (Fig. 5C). These data 
highlighted that the maximal increase in KV3.4 protein expression occurred in 
the hippocampus of young transgenic mice. KV3.4 subunits can form stable 
complexes with MiRP2; this interaction modifies the voltage-dependence of 
activation, speeds the recovery from inactivation, reduces the cumulative 
inactivation, and affects the conductance of KV3.4 channels (Pannaccione et 
al., 2007). Thus we performed immunoblot analysis with a MiRP2-specific 
antibody on protein extracts from WT and Tg2576 hippocampal tissue that 
revealed one band at 20 kDa, corresponding to MiRP2 (Abbott et al., 2001) 
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(Fig. 5D). Densitometric quantification showed that MiRP2 followed the same 
tendency of KV3.4 protein expression; in fact we observed a significant 
increase in MiRP2 protein expression in younger Tg2576 mice compared to 
age-matched WT (Fig. 5E). Thus, we observed the modulation both of KV3.4 
and its accessory component in Tg2576 mice. 
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Fig. 5 
 
Fig. 5 Aβ1-42 trimers deposition in young Tg2576 mice correlates with the over expression of 
KV3.4 Channel Subunits and its accessory subunit MiRP2. (A) Western Blot of Aβ1-42 trimers 
deposition and APP protein expression in young WT and Tg2576 mice evaluated in cerebellum, cerebral 
cortex, hippocampus and striatum. (B) Western Blot of KV3.4 protein expression evaluated in the 
hippocampus of WT and Tg2576 mice at different AD stages. (C) Densitometric analysis of KV3.4 protein 
expression normalized to α-tubulin levels. (D) Western Blot of MiRP2 protein expression evaluated in the 
hippocampus of WT and Tg2576 mice at different AD stages. (E) Densitometric analysis of MiRP2 
protein expression normalized to α-tubulin levels. The values are expressed as mean±SEM of 3 
independent experimental sections. *p≤ 0.05 versus their respective control, **p≤ 0.01 versus their 
respective control, *** p≤ 0.001 versus their respective control (Student’s t test and ANOVA). 
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6.3 Changes in KV3.4 and in its accessory subunit MiRP2 
protein expression are related to disease stage  
 
To confirm the involvement of KV3.4 in the early stages of AD, we performed 
Western Blot experiments on protein extracts obtained from elderly Tg2576 
mice (14, 16 and 18 months of age). We observed that the specific band at 
110 kDa, corresponding to native KV3.4, was reduced in the hippocampus of 
14 months old Tg2576 mice compared to age-matched WT mice (Fig. 6B, 
6C). By contrast KV3.4 protein expression was unchanged in 16 and 18 old 
Tg2576 mice compared to age-matched WT mice (Fig. 6B, 6C). In addition we 
performed immunoblot analysis with a MiRP2-specific antibody on protein 
extracts from elderly Tg2576 mice (Fig. 6D). Densitometric analysis showed 
that MiRP2 protein expression was unchanged in 16 and 18 old Tg2576 mice 
compared to age-matched WT mice (Fig. 6E). Moreover we evaluated the 
APP protein expression in the hippocampus of elderly Tg2576 mice compared 
to age-matched WT. As expected, we observed a significant enhance in APP 
protein expression in Tg2576 hippocampus compared to age-matched WT 
(Fig. 6A). Interestingly, in the late phase of AD we find the accumulation of 
high-molecular weight Aβ1-42 oligomers, protofibrils/fibrils and lastly plaques; 
whereas in the early phase of AD the predominant Aβ species are low-
molecular weight Aβ1-42  oligomers, specially Aβ1-42 dimers and trimers (Fig. 
5A). Thus, we performed immunoblot analysis to evaluate the species of Aβ1-
42  oligomers more prevalent in elderly Tg2576 mice. In particular we detected 
through a specific anti-Aβ1-42 antibody, Aβ56, nonamers and dodecamers of 
Aβ1-42 oligomers in Tg2576 hippocampus compared to age-matched WT (Fig. 
6A). We observed also a time dependent increase in Aβ1-42 oligomers 
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deposition in Tg2576 hippocampus. Collectively the data obtained showed 
that: 1) KV3.4 had a specific role in the early stages of AD; and 2) only low-
molecular weight Aβ1-42 oligomers were able to elicit a deregulation of KV3.4. 
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Fig. 6 
 
 
Fig. 6 Changes in KV3.4 and in its accessory subunit MiRP2 protein expression are related to 
disease stage . (A) Western Blot of Aβ1-42 oligomers deposition and APP protein expression in the 
hippocampus of Tg2576 mice compared to age-matched WT. (B) Western Blot of KV3.4 protein 
expression evaluated in the hippocampus of WT and Tg2576 mice at different AD stages. (C) 
Densitometric analysis of KV3.4 protein expression normalized to α-tubulin levels. (D) Western Blot of 
MiRP2 protein expression evaluated in the hippocampus of WT and Tg2576 mice at different AD stages. 
(E) Densitometric analysis of MiRP2 protein expression normalized to α-tubulin levels. The values are 
expressed as mean±SEM of 3 independent experimental sections. *p≤ 0.05 versus their respective 
control, **p≤ 0.01 versus their respective control, *** p≤ 0.001 versus their respective control (Student’s t 
test and ANOVA). 
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6.4 KV3.4 activity increases in hippocampal neurons obtained 
from Tg2576 mice 
 
To correlate the increase of KV3.4 protein expression in Tg2576 mice with 
electrophysiological activity we performed patch clamp experiments in whole 
cell configuration. In particular, we recorded hippocampal neurons obtained 
from WT and Tg2576 embryos at different days in vitro (DIV). We observed a 
significant increase of total potassium currents IK in Tg2576 hippocampal 
neurons compared to WT (Fig. 7A). Interestingly, the isolation of IA component 
from total potassium currents, showed the significant increase of this 
component in Tg2576 hippocampal neurons compared to WT hippocampal 
neurons (Fig. 7A-7C). Time-course experiments at different DIV (8-12-15 DIV) 
revealed that transgenic hippocampal neurons displayed an early increase of 
K+ current density compared to WT hippocampal neurons. We found, that K+ 
current density was significantly increased already at 8 DIV in culture, reached 
the maximal value at 12 DIV, and showed a less pronounced, but still 
significant, increase at 15 DIV (Fig. 7D) in the transgenic neurons respect WT. 
The up-regulated IA currents recorded in Tg2576 hippocampal neurons were 
inhibited by BDS-I, a well known blocker of KV3 family (Diochot et al., 1998; 
Yeung et al., 2005). The percentage of the BDS-I inhibition was higher in 
Tg2576 hippocampal neurons compared to WT (Fig. 7E). In addiction we 
performed immunocytochemical analysis to measure the expression levels of 
KV3.4 in Tg2576 and WT hippocampal neurons at 12DIV, when we observed 
the maximal increase of KV3.4 activity. We observed an increase in the 
expression of KV3.4 in Tg2576 hippocampal neurons compared to WT. More 
interestingly, KV3.4 immunosignal pattern was more different between WT and 
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Tg2576 cultured hippocampal neurons; in fact, we observed a plasma 
membrane localization and a punctuated staining pattern mostly confined 
throughout the neuropil in WT hippocampal neurons, whereas, in Tg2576 
hippocampal cells, the KV3.4 immunosignal was more confined to the soma 
plasma membrane (Fig. 7F). 
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Fig. 7 
 
Fig. 7 KV3.4 activity increases in hippocampal neurons obtained from Tg2576 mice. (A) Total 
outward K
+
 currents recorded from WT and Tg2576 hippocampal neurons in 12 DIV. (B) IDR currents 
recorded from WT and Tg2576 hippocampal neurons in 12 DIV. (C) IA currents obtained upon 
subtraction of IDR from IK currents recorded from WT and Tg2576 hippocampal neurons in 12 DIV. (D) 
Quantification of IA currents recorded in different DIV in Tg2576 hippocampal neurons compared to WT. 
(E) Quantification of IA currents recorded in Tg2576 hippocampal neurons expressed as a percentage of 
inhibition induced by 50 nM of BDS-I compared to WT. (F) Immunofluorescence images of Tg2576 and 
WT hippocampal neurons in 12 DIV displaying both KV3.4 protein expression and Hoechst-33258 
staining. The values are expressed as mean±SEM of 3 independent experimental sections. *p≤ 0.05 
versus their respective control, **p≤ 0.01 versus their respective control, *** p≤ 0.001 versus their 
respective control (Student’s t test and ANOVA). 
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6.5 KV3.4 over expression induces caspase-3 activation 
culminating in neuronal death  
 
We performed in vitro experiments to induce KV3.4 over expression in mouse 
hippocampal neurons, through transient transfection of KV3.4 and MiRP2 
cDNAs. At first, we assessed KV3.4 activity both in control hippocampal 
neurons and overexpressing KV3.4 and MiRP2 cDNAs. We observed a 
significant up-regulation in KV3.4 currents in neurons over expressing KV3.4 
and MiRP2 cDNAs compared to control (Fig. 8A-8B). The increase in KV3.4 
activity correlated with KV3.4 protein expression, indeed we found a significant 
raise in hippocampal neurons over expressing KV3.4 (Fig. 8C). It is well known 
that the cytoplasmic K+ loss promotes caspases and nucleases activation, 
which lead to apoptosis. Thus, we performed Western Blot analysis to 
evaluate caspase-3 activation, a specific key mediator of apoptosis in 
neuronal cells (D‟Amelio et al., 2003). In hippocampal neurons over 
expressing KV3.4 we observed a significant augment in caspase-3 activation 
(Fig. 8D), thus the deregulation of intracellular K+ concentration mediated by 
an increase of KV3.4 activity correlated with apoptosis. Subsequently, we 
analyzed caspase-3 activation in the hippocampus of young WT and Tg2576 
mice in which we observed the increase in KV3.4 protein expression. 
Interestingly, we found an increase in pro-caspase 3 expression in the 
hippocampus of young Tg2576 mice compared to age-matched WT; 
furthermore we detected a specific band of 17 kDa corresponding to cleaved 
caspase-3 only in Tg2576 mice (Fig. 8E). 
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Fig. 8 
 
Fig. 8 KV3.4 over expression induces caspase-3 activation. (A) IA currents obtained upon subtraction 
of IDR from IK currents in control hippocampal neurons and over-expressing KV3.4 and MiRP2 cDNAs. (B) 
Quantification of IA currents recorded in control hippocampal neurons and over-expressing KV3.4 and 
MiRP2 cDNAs. (C) Western Blot of KV3.4 protein expression on protein extracts obtained from control 
hippocampal neurons and over-expressing KV3.4 and MiRP2 cDNAs. (D) Western Blot of caspase-3 
protein expression on protein extracts obtained from control hippocampal neurons and over-expressing 
KV3.4 and MiRP2 cDNAs. (E) Western Blot of KV3.4 protein expression and caspase-3 on hippocampal 
tissue obtained from three old Tg2576 mice compared to age-matched WT. The values are expressed 
as mean±SEM of 3 independent experimental sections. *p≤ 0.05 versus their respective control, **p≤ 
0.01 versus their respective control, *** p≤ 0.001 versus their respective control (Student’s t test and 
ANOVA). 
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6.6 KV3.4 selective knockdown effect on KV3.4 protein 
expression in rat and mouse hippocampal neurons  
 
In order to verify the involvement of KV3.4 overexpression in caspases 
activation and in the apoptotic cell death, we selectively knockdown KV3.4 
through gene silencing using RNA interfering (RNAi). We tested specific 
siRNA in two different in vitro models. Firstly we performed KV3.4 silencing in 
rat hippocampal neurons to identify the siRNA able to target rat KV3.4 genes. 
We transfected rat hippocampal neurons with two siRNA specific for rat Kcnc4 
genes: Rn_LOC684516_1 and Rn_LOC684516_2. We incubated neurons for 
48 hours with two different concentrations (10nM and 20nM) for each siRNA. 
Western Blot analysis showed a significant down-regulation of KV3.4 protein 
expression in hippocampal neurons with the siKV3.4 Rn_LOC684516_2 
compared to control neurons (Fig. 9A). Densitometric analysis showed the 
maximal reduction in KV3.4 protein expression in presence of 20nM of siKV3.4 
Rn_LOC684516_2 (Fig. 9A). By contrast, we did not observe a difference in 
KV3.4 protein expression in hippocampal neurons treated with siKV3.4 
Rn_LOC684516_1 compared to control neurons (Fig. 9B). In addition we 
transfected mouse hippocampal neurons with three siRNA specific for mouse 
Kcnc4 genes: Mm_Kcnc4_4, Mm_Kcnc4_5, Mm_Kcnc4_6. We incubated 
neurons for 48 hours with 20nM of each siRNA. Western Blot analysis 
revealed that the siRNA with the maximal efficacy to reduce KV3.4 protein 
expression was Mm_Kcnc4_5 (Fig. 9C). In fact, densitometric analysis 
showed a significant reduction in KV3.4 protein expression in presence of 
20nM of siKV3.4 Mm_Kcnc4_5 compared to control neurons (Fig. 9C). 
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Fig. 9 
 
Fig. 9 Effect of KV3.4 selective knockdown on KV3.4 protein expression in rat and mouse 
hippocampal neurons. (A) Western Blot and densitometric analysis of KV3.4 protein expression in rat 
hippocampal neurons treated with siRNA Rn_LOC684516_2. (B) Western Blot and densitometric 
analysis of KV3.4 protein expression in rat hippocampal neurons treated with siRNA Rn_LOC684516_1. 
(C) Western Blot and densitometric analysis of KV3.4 protein expression in mouse hippocampal neurons 
treated with siRNA Mm_Kcnc4_4, Mm_Kcnc4_5, Mm_Kcnc4_6. The values are expressed as 
mean±SEM of 3 independent experimental sections. *p≤ 0.05 versus their respective control, **p≤ 0.01 
versus their respective control, *** p≤ 0.001 versus their respective control (Student’s t test and ANOVA). 
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6.7 KV3.4 selective knockdown prevents caspase-3 activation 
and apoptotic events in Tg2576 mice  
 
To investigate the role of KV3.4 over-expression in the induction of apoptotic 
cell death we performed in vivo experiments in order to knockdown KV3.4 
gene. We silenced KV3.4 by intracerebroventricular (icv) administration of 
siKV3.4 Mm_Kcnc4_5, specific to mouse KV3.4 genes, previously tested in in 
vitro models. We treated three months old WT and Tg2576 mice with 5µM of 
siKV3.4 Mm_Kcnc4_5 for 72 hours; the experimental procedure required 
multiple administration, at least one every 24 hours. At the end of 72 hours 
animals were sacrificed, brains were collected and homogenized with a 
specific lysis buffer in order to obtain total protein lysate. Western Blot analysis 
on protein extracts showed that siKV3.4 Mm_Kcnc4_5 also in vivo was able to 
knockdown KV3.4. In particular, we observed a reduction in KV3.4 protein 
expression both in WT and Tg2576 mice treated with siRNA compared to WT 
mice without siKV3.4 (Fig. 10A) and Tg2576 mice without siKV3.4, respectively 
(Fig. 10B). Furthermore, we studied caspases activation in the presence and 
in the absence of siKV3.4. In Tg2576 mice we observed: 1) the increase of 
pro-caspase 3 protein expression compared to age-matched WT mice; 2) the 
presence of active caspase-3 (Fig. 10C-10D). Interestingly, densitometric 
quantification showed that the treatment with siKV3.4 counteracted pro-
caspase 3 increase (Fig. 10E). and caspase 3 activation observed in Tg2576 
mice. Upon apoptotic stimulation, initiator caspases, such as caspase-9 are 
activated. The activated upstream caspases further process downstream 
executioner caspases: caspase 3 and caspase 6, thereby initiating caspase 
cascade leading to apoptosis. Thus, we also evaluated the effect of siKV3.4 on 
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pro-caspase 6. In Tg2576 mice we observed the rice of pro-caspase 6 protein 
expression compared to age-matched WT mice (Fig. 10C-10D). Interestingly, 
densitometric quantification showed that the treatment with siKV3.4 neutralized 
pro-caspase 6 increase observed in Tg2576 mice (Fig. 10F).  
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Fig. 10 
 
Fig. 10 KV3.4 selective knockdown prevents caspase-3 activation and apoptotic events in Tg2576 
mice. (A) Western Blot and densitometric analysis of KV3.4 protein expression on protein extracts 
obtained from three months old WT mice in the presence and in the absence of siKV3.4. (B) Western 
Blot and densitometric analysis of KV3.4 protein expression on protein extracts obtained from three 
months old Tg2576 mice in the presence and in the absence of siKV3.4. (C) Western Blot of pro-caspase 
6, pro-caspase 3 and caspase 3 protein expression on protein extracts obtained from three months old 
WT mice in the presence and in the absence of siKV3.4. (D) Western Blot of pro-caspase 6, pro-caspase 
3 and caspase 3 protein expression on protein extracts obtained from three months old Tg2576 mice in 
the presence and in the absence of siKV3.4. (E) Densitometric analysis of pro-caspase 3 protein 
expression on protein extracts obtained from three months old WT and Tg2576 mice, in the presence 
and in the absence of siKV3.4. (F) Densitometric analysis of pro-caspase 6 protein expression on protein 
extracts obtained from three months old WT and Tg2576 mice, in the presence and in the absence of 
siKV3.4. The values are expressed as mean±SEM of 3 independent experimental sections. *p≤ 0.05 
versus their respective control, **p≤ 0.01 versus their respective control, *** p≤ 0.001 versus their 
respective control (Student’s t test and ANOVA 
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6.8 KV3.4 selective knockdown reduces Aβ production and 
trimers deposition in Tg2576 mice, improving memory 
performance 
 
Caspases display primary specificity for aspartic acid residues. To date, more 
then 280 proteins have been shown to be substrates of caspases in 
mammalian cells (Fischer et al., 2003; Tesco et al., 2003). Among them we 
find proteins involved in cell death, cell cycle regulation, cytoskeleton 
organization, DNA and RNA metabolism, signal transduction, cytokine 
maturation, and gene transcription. Recently, it has been demonstrated that 
APP is also a substrate for caspase cleavage, leading to an increase in Aβ 
production (Gervais et al., 1999; Lu et al., 2003; D‟Amelio et al., 2010). Thus 
we evaluated if the silencing of KV3.4 could modify Aβ production and trimers 
deposition in Tg2576 mice. We measured by Western Blot experiments the 
levels of Aβ1-42 trimers in the absence and in the presence of siKV3.4 in 
Tg2576 mice. Firstly, we observed a specific band of 15 kDa corresponding to 
Aβ1-42 trimers only in Tg2576 mice whereas in WT mice we did not observe Aβ 
deposition (Fig. 11A). Notably, in the presence of siKV3.4 we found a 
significant reduction in the levels of Aβ1-42 trimers in Tg2576 (Fig. 11A). We 
could assume the existence of indirect link between KV3.4 overexpression, 
caspases activation and Aβ1-42 trimers deposition. In fact, the silencing of 
KV3.4 prevented caspases activation, reduced APP alternative cleavage by 
caspases and in turn reduced Aβ1-42 formation in Tg2576 mice. Aβ aggregation 
has been recognized as a necessary condition for toxicity and it has been 
hypothesized that dimers and trimers of Aβ are the principal toxic species 
(Hung et al., 2008). Moreover, recent studies showed that Aβ oligomers can 
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inhibit hippocampal LTP and that Aβ1-42 dimers and trimers accumulate at the 
same time as memory impairment begins in Tg2576 mice (Kawarabayashi et 
al., 2004). Thus, we evaluated memory performance of Tg2576 mice in the 
presence and in the absence of KV3.4 silencing, by T-Maze spontaneous 
alternation test. This behavioral test (described in detail in Chapter 5: Materials 
and Methods) allows the evaluation of exploratory ability and memory 
performance, especially the spatial and working memory. We observed that 
Tg2576 mice exhibited impaired exploration ability, spatial learning and 
memory abilities, as indicated by fewer alternative choices and longer latency 
in the T-maze test. Interestingly, the silencing of KV3.4 ameliorated exploration 
ability and memory performance in Tg2576 mice. In fact, Tg2576 mice in the 
presence of KV3.4 silencing showed an increase in the percentage of 
alternation compared to Tg2576 mice without siKV3.4 (Fig. 11B); Tg2576 mice 
with siKV3.4 showed a reduction in the latency time necessary to reach the 
goal arm compared to Tg2576 mice without siKV3.4 (Fig. 11B). Furthermore, 
APP transgenic models show not only cognitive decline but also non-cognitive 
symptoms associated with the disease, including anxiety, aggression, 
locomotor hyperactivity (Walker et al., 2011). Therefore, we investigated 
simultaneously locomotion, exploration and anxiety with Open Field Test 
(described in detail in Chapter 5: Materials and Methods). Tg2576 mice 
travelled a greater average distance in comparison with WT mice, indicating a 
locomotor hyperactivity of transgenic mice. Tg2576 mice in the presence of 
siKV3.4 displayed a significant reduction in the total distance traveled 
compared to Tg2576 without siKV3.4 (Fig. 11C). 
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Fig. 11 
 
Fig. 11 KV3.4 selective knockdown reduces Aβ production and trimers deposition in Tg2576 mice, 
improving memory performance. (A, left panel) Western Blot of Aβ1-42 trimers protein expression on 
protein extracts obtained from three months old WT and Tg2576 mice in the presence and in the 
absence of siKV3.4. (A, right panel) Densitometric analysis of Aβ1-42 trimers protein expression on 
protein extracts obtained from three months old Tg2576 mice in the presence and in the absence of 
siKV3.4 (B, left panel) Evaluation of the percentage of alternation (number of turns in each goal arm) in 
the T-Maze Spontaneous Alternation Test. (B, right panel) The latency time necessary to reach the goal 
arm calculate for each experimental groups in the T-Maze Spontaneous Alternation Test. (C) Evaluation 
of total distance traveled by animals in the Open Field Test calculate for each experimental groups. The 
values are expressed as mean±SEM of 3 independent experimental sections. *p≤ 0.05 versus their 
respective control, **p≤ 0.01 versus their respective control, *** p≤ 0.001 versus their respective control 
(Student’s t test and ANOVA). 
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6.9 BDS 1-8 fragment, obtained from full length BDS-I toxin, 
could be an innovative pharmacological strategy to block 
KV3.4 in Tg2576 mice 
 
Sea anemone venom contains toxins that are able to active voltage-sensitive 
Na+ channels or block K+ channels. In particular Anemonia sulcate produced 
two toxins, BDS-I and BDS-II, which differ in only two positions (Ser-7 instead 
of Pro and Gly-11 instead of Asp). Both peptides have 43 aminoacids and are 
cross-linked by three disulfide bridges. BDS-I, but not BDS-II, is able to inhibit 
KV3.4 currents in a reversible manner, with an IC50 value of 47 nM (Diochot et 
al., 1998). To find an innovative strategy to inhibit KV3.4 potassium channel, 
we synthetized more fragments from full length BDS-I in order to identify the 
smaller portion of toxin that preserves the ability to block KV3.4 currents. We 
chose CHO cell line as host cells for KV3.4 and MiRP2 cDNAs transient 
transfection. First of all we evaluated the transfection efficiency by Western 
Blot analysis on protein extracts from control CHO cells and CHO cells plus 
KV3.4 and MiRP2 cDNAs. KV3.4-specific antibody revealed two band, at 75 
kDa and 110 kDa, that correspond to immature and mature KV3.4 subunit 
respectively, only in CHO cells plus KV3.4 and MiRP2 cDNAs (Fig. 12A). 
Electrophysiological experiments showed a typical K+ currents mediated by 
KV3.4, only in CHO cells plus KV3.4 and MiRP2 cDNAs (Fig. 12A). BDS1-8 
fragment, containing the first eight aminoacids from full BDS-I, has been the 
first fragment tested. We supposed that this fragment could have a critical role 
in the inhibition of KV3.4 currents because contained one of two positions 
which differ between BDS-I and BDS-II. In particular, Proline in position 7 of 
BDS-I which differ from Serine in position 7 of BDS-II could explain the 
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property of BDS-I, but not of BDS-II, to block KV3.4 currents. 
Electrophysiological experiments performed in CHO cells plus KV3.4 and 
MiRP2 cDNAs showed that BDS1-8 fragment was able to inhibit KV3.4 
currents in a concentration dependent manner (Fig. 12B). Interestingly, 30nM 
of BDS1-8 were able to inhibit KV3.4 currents; moreover 100nM of BDS-I were 
able to totally block KV3.4 activity (Fig. 12B). Pannaccione and colleagues 
(2007), demonstrated that BDS-I prevented Aβ1–42-induced apoptosis in NGF-
differentiated PC-12 cells and in hippocampal neurons. Thus we tested the 
ability of BDS1-8 fragment to prevent apoptotic mechanisms in presence of a 
death stimulus, such as Aβ1-42 treatment that triggers an increase in KV3.4 
expression and activity. BDS 1-8 (100 nM), was able to significantly prevent 
the abnormal nuclear morphology induced by the exposure of NGF-
differentiated PC-12 cells to Aβ1–42 (5 µM for 24 h), as detected by the Hoechst 
32258 dye staining (Fig. 12C). Interestingly, BDS1-8 prevention of Aβ1–42-
induced apoptosis occurred through its ability to inhibit KV3.4 activity. Nuclear 
morphology quantification assessment with Hoechst 33258 dye staining 
revealed that BDS1-8 was able to avoid the increase in the percentage of 
abnormal nuclei induced by Aβ1–42 treatment (Fig. 12E). Moreover BDS1-8 
treatment was also able to prevent caspase-3 activation that we observed 
after Aβ1–42 exposure (Fig. 12E).  
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Fig. 12 
 
 
Fig. 12 BDS 1-8 fragment, obtained from full BDS-I toxin, could be an innovative pharmacological 
strategy to block KV3.4 in Tg2576 mice. (A, left panel) Western Blot analysis of KV3.4 protein 
expression on protein extracts obtained from control CHO cells and CHO cells plus KV3.4 and MiRP2 
cDNAs. (A, right  panel) Total outward K
+
 currents recorded from control CHO cells and CHO cells plus 
KV3.4 and MiRP2 cDNAs. (B) Total outward K
+
 currents recorded from CHO cells plus KV3.4 and MiRP2 
cDNAs in the absence and in the presence of 30nM, 100nM of BDS1-8 fragment. (C) Quantification of 
total outward K
+ 
currents recorded from CHO cells plus KV3.4 and MiRP2 cDNAs in the absence and in 
the presence of 30nM, 100nM of BDS1-8 fragment. (D) Assessment of nuclear morphology with 
Hoechst-33258 in NGF-differentiated PC-12 cells exposed for 24h to only Staurosporine, to only 5 µM 
Aβ1–42, to only 50nM BDS-I, to only 100nM BDS1-8, to Aβ1–42+ 50nM BDS-I, to Aβ1–42+ 100nM BDS-1-8. 
(E) Quantification of abnormal nuclear morphology and evaluation of caspase-3 activation in NGF-
differentiated PC-12 cells exposed for 24h to only Staurosporine, to only 5 µM Aβ1–42, to only 50nM 
BDS-I, to only 100nM BDS1-8, to Aβ1–42+ 50nM BDS-I, to Aβ1–42+ 100nM BDS-1-8. The values are 
expressed as mean±SEM of 3 independent experimental sections. *p≤ 0.05 versus their respective 
control, **p≤ 0.01 versus their respective control, *** p≤ 0.001 versus their respective control, #p≤ 0.001 
versus Aβ1–42 groups (Student’s t test and ANOVA). 
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6.10 Aβ1-42 exposure increases KV3.4 expression and induces 
the astrocytes activation. 
 
KV channels are found in both excitable and non-excitable cell types. They 
have a critical role in neuronal and muscular excitability, in the regulation of 
action potential frequency and membrane potential, in the neurotransmitter 
release. However, their role in the non-excitable glial cell type remain yet 
unclear. Astrocytes, the most abundant glial cell type in CNS, serve as 
neuronal support and also as homeostasis regulators. Bekar and colleagues 
(2005), through immunocytochemical evaluation and RT-PCR analysis, has 
been demonstrated the presence of KV3.4 subunit in hippocampal astrocyte 
cultures (Bekar et al., 2005). However its expression and activity under AD 
pathology was never explored. Thus we studied the expression and the 
functional role of KV3.4 subunit in astrocyte cultures treated with Aβ1-42 peptide. 
Firstly we performed Western Blot analysis in order to evaluate KV3.4 and 
GFAP protein expression in astrocytes after Aβ1-42 exposure. We found a 
significant increase in KV3.4 (Fig. 13A) and GFAP (Fig. 13B) protein 
expression in astrocytes treated with 5µM of Aβ1-42 for 48 hours compared to 
control astrocytes. We performed experiments with the cytoskeletal marker 
phalloidin in order to assess the astrocytes morphology and the nuclear dye 
Hoechst- 33342 in order to evaluate nuclear changes following Aβ1-42 
treatment. Primary cultured astrocytes exposed to 5 µM of Aβ1-42 for 48 hours 
showed more main cellular processes than untreated astrocytes (Fig. 13C). 
Moreover, little changes were detected in their nuclear morphology (Fig. 13C) 
but no apoptotic damage was observed in astrocytes after 48 hours of Aβ1-42. 
Thus, Aβ1-42 elicited astrocytes activation, as confirmed by the increase in 
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GFAP protein expression. Double immunofluorescence experiments with the 
anti-KV3.4 and anti-GFAP antibodies revealed a more pronounced 
immunoreactivity for both KV3.4 and GFAP when astrocytes were exposed to 
Aβ1-42 for 48 hours (Fig. 13D). Interestingly, immunocytochemistry experiments 
revealed that the KV3.4 and GFAP immunosignals overlapped both in control 
astrocytes (Fig. 13D, c) and in Aβ1-42-treated astrocytes (Fig. 13D, f). 
Furthermore the exposure to Aβ1-42 induced an improve in the co-expression of 
KV3.4 and GFAP proteins. To assess whether the overlap between GFAP and 
KV3.4 immunostaining in the astrocytes was due to a direct binding between 
the two proteins, cell lysates from control and Aβ1-42-treated astrocytes were 
immunoprecipitated with anti-GFAP or anti-KV3.4 antibodies and 
immunoblotted with anti-KV3.4 antibodies or anti-GFAP, respectively. When 
we immunoprecipitated for KV3.4 and then immunoblotted for GFAP we 
revealed a specific band at 50 kDa corresponding to GFAP both in control 
conditions and in Aβ1-42-treated astrocytes (Fig. 13E). Whereas when we 
immunoprecipitated for GFAP and then immunoblotted for KV3.4 we found a 
specific band at 75 kDa corresponding to KV3.4 both in control conditions and 
in Aβ1-42-treated astrocytes (Fig. 13E). 
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Fig. 13 
 
Fig. 13 Aβ1-42 exposure increases KV3.4 expression and induces the astrocytes activation. (A) 
Western Blot analysis and densitometric analysis of KV3.4 protein expression on protein extracts 
obtained from primary astrocytes under control conditions or 48 hours after Aβ1-42 exposure. (B) Western 
Blot analysis and densitometric analysis of GFAP protein expression on protein extracts obtained from 
primary astrocytes under control conditions or 48 hours after Aβ1-42 exposure. (C, left panel) Light 
microscopy images displaying phalloidin and Hoechst-33258 double-labeling in single representative 
primary astrocytes under control conditions (a) or 48 hours after Aβ1-42 exposure(b). The top frames in a-
b show the nuclear morphology. (C, right panel) Quantitative analysis of the number of astrocytic 
processes for cell detected with phalloidin labeling under control conditions or 48 hours after Aβ1-42 
exposure. (D) Confocal double immunofluorescence images of primary astrocytes displaying both KV3.4 
(red) and GFAP (green) immunoreactivities under control conditions (a-c) or 48 hours after Aβ1-42 
exposure (d-i). (E) Total astrocyte cell extract (1mg) was immunoprecipitated with anti-GFAP or anti-
Kv3.4 antibodies and then immunoblotted with anti-KV3.4 or anti-GFAP antibodies respectively. L, 
lysates; C, control. The values are expressed as mean±SEM of 3 independent experimental sections. 
*p≤ 0.05 versus their respective control, **p≤ 0.01 versus their respective control, *** p≤ 0.001 versus 
their respective control (Student’s t test and ANOVA). 
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6.11 Aβ1-42 exposure increases KV3.4 activity in primary 
astrocytes, whereas the KV3.4 silencing prevents Aβ1-42-effect. 
 
Electrophysiological recordings by patch clamp in astrocytes exposed for 48 
hours to Aβ1-42 displayed a significant up-regulation of the transient outward 
potassium currents IA compared to control cells (Fig. 14A). Upon bath-
application of the selective blocker of KV3.4 channels, BDS-I (50nM), we 
observed a significant inhibition of IA currents both in control and in Aβ1-42-
treated astrocytes (Fig.14B). We observed a significant inhibition of KV3.4 
currents in presence of BDS-I both in control astrocytes and in Aβ1-42-treated 
astrocytes (Fig. 14B). To further confirm the contribution of KV3.4 function to 
the upregulated IA currents in astrocytes exposed to Aβ1-42 we knockdown 
KV3.4 subunits with a selective siRNA in the presence or in the absence of 
amyloid fragment. Electrophysiological recordings revealed that KV3.4 
silencing was able to avoid the up-regulation of the IA currents triggered by 
Aβ1-42 treatment (Fig. 14C). Quantification of IA currents showed a significant 
reduction of IA component of IK currents in astrocytes in the presence of 
selective KV3.4 siRNA (Fig. 14D). Moreover, we observed a more pronounced 
decrease in IA currents in astrocytes with the silencing of KV3.4, treated with 
Aβ1-42 peptide (Fig. 14D). 
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Fig. 14 
 
 
Fig. 14 Aβ1-42 exposure increases KV3.4 activity in primary astrocytes, whereas the KV3.4 
silencing prevents Aβ1-42-effect. (A, left panel) Representative traces of voltage-isolated fast 
inactivating currents (IA) recorded from primary astrocytes under control conditions and 48 hours after 
Aβ1-42 exposure. (A, right panel) IA currents quantification represented in the left panel. (B, left panel) 
current-voltage relationships for isolated IA under control conditions and 48 hours after Aβ1-42 exposure 
both in the presence or in the absence of 50nM BDS-I. (B, right panel) IA currents quantification 
represented in the left panel. (C, left panel) Representative traces of the outward K
+
 currents (IK) 
recorded from control (a), control plus siKV3.4 (c), after Aβ1-42 for 48 hours (b), after Aβ1-42 for 48 hours 
plus siKV3.4 (d) in primary astrocytes. (C, right panel) quantification of IA currents recorded from control, 
control plus siKV3.4, after Aβ1-42 for 48 hours, after Aβ1-42 for 48 hours plus siKV3.4 in primary astrocytes. 
The values are expressed as mean±SEM of 3 independent preparation of primary astrocyte cultures 
(n=12 cells in each cell culture and for each group). *p≤ 0.05 versus their respective control, **p≤ 0.01 
versus their respective control, *** p≤ 0.001 versus their respective control (Student’s t test and ANOVA). 
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6.12 Silencing of KV3.4 significantly reduced astrocytes 
activation in Tg2576 mice in the early stages of AD. 
 
To test the contribution of KV3.4 increased expression and activity to the early 
astrocytes activation in Tg2576 mouse brain, we explored in vivo whether the 
selective knockdown of the KV3.4 gene could affect astrocyte activation. To 
this aim, we silenced KV3.4 subunits with a selective siRNA and analyzed 
GFAP protein levels in brain lysates from both Tg2576 and WT mice. Western 
Blot analysis revealed that GFAP protein levels was upregulated in Tg2576 
mice compared to age-matched WT (Fig. 15A) By contrast, intracerebral 
ventricular infusion of siRNA significantly reduced astrocytes activation in 
Tg2576 mice as detected by the significant decrease in the optical density of 
the 50kDa band (GFAP) (Fig. 15C). 
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Fig. 15 
 
Fig. 15 Silencing of KV3.4 significantly reduced astrocyte activation in Tg2576 mice in the early 
stages of AD. (A) Western Blot analysis and densitometric  analysis of GFAP protein expression in the 
brain of WT and Tg2576 mice. (B) Western blot analysis of GFAP in the brain of WT mice in the absence 
or in the presence of siKV3.4. (C) Western blot analysis and densitometric analysis of GFAP protein 
expression in the brain of Tg2576 in the absence or in the presence of siKV3.4. The values are 
expressed as mean±SEM of 3 independent experimental sections. *p≤ 0.05 versus their respective 
control, **p≤ 0.01 versus their respective control, *** p≤ 0.001 versus their respective control (Student’s t 
test and ANOVA). 
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 Chapter 7: Discussion 
 
This PhD thesis demonstrated that KV3.4 potassium channel subunit has a 
critical role in the early stages of AD. In fact we observed an increase in KV3.4 
protein expression in the hippocampus of young Tg2576 mice (3 months old), 
whereas we did not observe a significant modification in elderly Tg2576 mice 
(14-18 months old). In addition we observed a singular tendency of KV3.4 
expression in WT and Tg2576 mice. In the hippocampus of 3 months old WT 
mice we found the lower levels of KV3.4, whereas in the hippocampus of 12 
months old WT mice KV3.4 expression reached the peak, suggesting a key 
role of KV3.4 in the adulthood and aging. Progressive increase in the 
expression and the achievement of a peak in adulthood suggested that KV3.4 
could contribute to the maturation of the neuronal electrical activity. Moreover, 
in Tg2576 mice we reported an anticipation of the events described in WT 
mice. In fact KV3.4 maximal protein expression occurred in the hippocampus 
of 3 months old Tg2576 mice, whereas in 12 months old transgenic mice we 
noted a significant reduction. In addition, we investigated the protein 
expression of MiRP2, a neuronal β-subunit co-assembling with KV3.4 that 
plays a central role in the control of its biophysical properties and 
pharmacological profile (Abbott et al., 2001). MiRP2 protein expression 
followed the same trend of KV3.4; in fact we observed its modulation only in 
the early stages of AD pathogenesis. Pannaccione et al (2007) found in in vitro 
models that Aβ1-42 exposure induced the simultaneously modulation of KV3.4 
and its accessory component. Our results, obtained in an in vivo model of AD, 
such as Tg2576 mice, were in agreement with those performed in vitro with 
Aβ1-42 treatment. In the early phase of AD we found the deposition of Aβ1-42 
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oligomers of low molecular weight such as dimeric and trimeric forms 
(Kawarabayashi et al., 2004). In particular, we found Aβ1-42 trimers deposition 
in 3-months old transgenic mice when we observed the maximal increase in 
KV3.4 and MiRP2 expression, suggesting the deleterious effects triggered by 
trimers deposition in AD brain. Recently, it has been demonstrated that 
primary neurons from Tg2576 mice recapitulate the in vivo localization and 
accumulation of Aβ1-42 with time in culture (Takahashi et al., 2004). Thus we 
measured KV3.4 activity by patch clamp in hippocampal neurons obtained 
from WT and transgenic embryos at different DIV. Electrophysiological 
recordings displayed a substantial increase in total outward K+ currents in 
transgenic hippocampal neurons compared to WT neurons. In addition we 
found an increase in IA amplitude, previously isolated with the voltage 
subtraction protocol from IK currents, in transgenic neurons. Interestingly, we 
found an early increase in transgenic neurons at 8 and 12 DIV whereas at 15 
DIV we observed a down-regulation in IA currents. These results supported the 
concept that KV3.4 has a key role in early stages of AD, contributing to 
neuronal hyperexcitability. It has been hypothesized that Aβ1-42 accumulation 
makes neurons hyperexcitable and susceptible for epileptiform activity. In APP 
transgenic mice it has been found the onset of spontaneous non-convulsive 
seizure in cortical and hippocampal networks (Palop et al., 2007). Moreover, 
AD patients also have a higher incidence of seizures compared to normal 
populations. Indeed, the epileptic activity is predominantly in AD patients with 
early-onset dementia and during the earlier stages of the disease. 
Interestingly, mice overexpressing human WT or mutated APP showed 
premature death, with a peak around 3-4 months of age before the finding of 
first plaques. Minkeviciene and colleagues (2009) reported that epileptic 
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seizure may trigger premature death in APP transgenic mice. In agreement 
with biochemical and electrophysiological results, the immunocytochemical 
analysis confirmed that in transgenic mice there was an increase in KV3.4 
expression associated with an altered subcellular distribution of this protein. In 
fact in transgenic hippocampal neurons we observed a more intense KV3.4 
immunosignal mainly confined to the somatic plasma membrane, in 
comparison with WT hippocampal neurons in which the fluorescent signal was 
mostly distributed through the neuropil. This different KV3.4 distribution could 
be induced by the alteration of the cytoskeletal integrity provoked by Aβ1-42 
accumulation. Intriguingly, it has been demonstrated that [K+]i play a key role 
in cell survival. Cytoplasmic K+ loss has been shown to favor activation of 
caspases and nucleases, which lead to apoptosis (Hughes et al., 1997; Cain 
et al., 2001). K+ efflux has been proposed to be a pro-apoptotic factor, 
consequently plasma membrane potassium channels represent good 
candidates for apoptosis regulation. Pannaccione and colleagues (2007) have 
demonstrated that Aβ1-42 peptide induced a selective up-regulation of KV3.4 
channel subunits and that this event was associated with an increase in KV3.4 
currents. In addition, hippocampal neurons and NGF-differentiated PC-12 cells 
over expressing KV3.4 showed an apoptotic nuclear process, as revealed by 
caspase-3 activation and by Hoechst 33258-monitored abnormal nuclear 
morphology, thus suggesting a possible link between the enhanced 
expression and function of this K+ channel and the neurotoxic consequences 
of Aβ exposure. Intriguingly in Tg2576 mice, in the early phase of AD, the up-
regulation of KV3.4 expression and activity was accompanied by the increase 
in pro-caspase 3 and the activation of caspase-3. Thus KV3.4 potassium 
channel subunit was implicated in AD pathogenesis, in particular had a pivotal 
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role in the onset of AD symptoms. Consistently with this hypothesis we 
provided evidence that the silencing of KV3.4 in the brain of early Tg2576 mice 
(3 months old) strongly reducing KV3.4 expression, prevented the activation of 
caspase-3. In addition, in Tg2576 mice we observed the rice of pro-caspase 6 
protein expression and that siKV3.4 was able to prevent this increase. 
Recently, several studies have demonstrated that APP is also a substrate for 
caspases cleavage, suggesting an additional role of caspases in the 
neurodegeneration characteristic of AD. In fact, a second mechanism for APP 
processing involves caspase-induced cleavage of APP. Furthermore, 
caspases activation leads to an increase of amyloidogenic fragments and Aβ 
peptide (Gervais et al., 1999; Lu et al., 2003; D‟Amelio et al., 2010). Thus we 
evaluated if the silencing of KV3.4 could modify Aβ production and trimers 
deposition in Tg2576 mice. Notably, in the presence of siKV3.4 we found a 
significant reduction in the levels of Aβ1-42 trimers in Tg2576 mice. We could 
assume the existence of an indirect link between KV3.4 over-expression, 
caspases activation and Aβ1-42 trimers deposition. In fact, the silencing of 
KV3.4 in Tg2576 mice prevented caspases activation, reduced APP alternative 
cleavage by caspases and in turn reduced Aβ1-42 formation. Aβ aggregation 
has been recognized as a necessary condition for toxicity and it has been 
hypothesized that dimers and trimers of Aβ are the principal toxic species 
(Hung et al., 2008). Moreover, recent studies showed that Aβ oligomers can 
inhibit hippocampal LTP and that Aβ1-42 dimers and trimers accumulate in 
Tg2576 mice in the same time when memory impairment begins 
(Kawarabayashi et al., 2004). Thus, we evaluated memory performance of 
Tg2576 mice through T-Maze spontaneous alternation test. Tg2576 mice 
exhibited impaired exploration ability, spatial learning and memory abilities, as 
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indicated by fewer alternative choices and longer latency. Interestingly, the 
silencing of KV3.4 ameliorated exploration ability and memory performance. In 
fact, Tg2576 mice in the presence of KV3.4 silencing showed an increase in 
the percentage of alternation and a reduction in the latency time necessary to 
reach the goal arm, compared to Tg2576 mice without siKV3.4. Furthermore, 
APP transgenic models show not only cognitive decline but also non-cognitive 
symptoms associated with the disease, including anxiety, aggression, 
locomotor hyperactivity (Walker et al., 2011). Furthermore we investigated 
simultaneously locomotion, exploration and anxiety with Open Field test. 
Tg2576 mice travelled a greater average distance in comparison with WT 
mice, demonstrating a locomotor hyperactivity. Tg2576 mice in the presence 
of siKV3.4 displayed a significant reduction in the total distance travelled 
compared to Tg2576 without siKV3.4. These results suggested a critical role of 
KV3.4 in the progression and development of AD. Intriguingly, siKV3.4 
ameliorating memory performance and non-cognitive symptoms associated 
with AD could become a new pharmacological target in the care of AD. To 
achieve this aim we found a new synthetic compound, BDS1-8, containing the 
first eight aminoacids from full lenght BDS-I that as well known blocks KV3.4 
currents. Electrophysiological experiments performed in CHO cells plus KV3.4 
and MiRP2 cDNAs showed that BDS1-8 fragment was able to inhibit KV3.4 
currents in a concentration dependent manner. Furthermore BDS1-8 was able 
to significantly prevent the abnormal nuclear morphology induced by Aβ1–42 
exposure (5 µM for 24 h) in NGF-differentiated PC-12 cells, as detected by 
Hoechst 32258 dye staining. Nuclear morphology assessment with Hoechst 
33258 dye staining revealed that BDS1-8 was able to avoid the increase in the 
percentage of abnormal nuclei induced by Aβ1–42 treatment. Moreover BDS1-8 
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treatment was also able to prevent caspase-3 activation that we observed 
after Aβ1–42 exposure. Based on these observations, we proposed that 
reducing the elevated levels of KV3.4 we may provide a promising strategy to 
slowing down AD development and progression. In the last years the new 
pharmacological strategies for AD treatment are focused on the possibility to 
block or modify the course of AD. To block the progression of the disease the 
new pharmacological strategies should interfere with the pathogenic steps 
responsible for the clinical symptoms, including the deposition of Aβ1-42 
peptide. Thus the inhibition of KV3.4 in the early stages of AD could became a 
promising strategy to slowing down Aβ1–42 formation. In the last phase of our 
study we investigated the role of KV3.4 in astrocytes. Bekar and colleagues 
(2005) have demonstrated the presence of KV3.4 subunit in hippocampal 
astrocyte cultures (Bekar et al., 2005). However their expression and activity 
under AD pathology was never explored. Thus we studied the expression and 
the functional role of KV3.4 subunit in astrocyte cultures treated with Aβ1-42 
peptide. We found a significant increase in KV3.4 and GFAP protein 
expression in astrocytes treated with 5µM of Aβ1-42 for 48 hours compared to 
control astrocytes. Moreover, primary cultured astrocytes exposed to 5 µM of 
Aβ1-42 for 48 hours showed more main cellular processes than untreated 
astrocytes, little changes were detected in their nuclear morphology but no 
apoptotic damage was observed. Thus, Aβ1-42 elicited astrocytes activation, as 
confirmed by the increase in GFAP protein expression. Double 
immunofluorescence experiments with the anti-KV3.4 and anti-GFAP 
antibodies revealed a more pronounced immunoreactivity for both KV3.4 and 
GFAP when astrocytes were exposed to Aβ1-42 for 48 hours. Interestingly, 
immunocytochemistry experiments revealed the presence of intense overlap 
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between KV3.4 and GFAP immunosignals in control astrocytes and in Aβ1-42-
treated astrocytes. Furthermore the exposure to Aβ1-42 induced an 
improvement in the co-expression of KV3.4 and GFAP proteins. 
Immunoprecipitation experiments performed with anti-GFAP or anti-KV3.4 
antibodies demonstrated that the overlap between GFAP and KV3.4 
immunostaining in the astrocytes was due to a direct binding between the two 
proteins. Electrophysiological recordings by patch clamp in astrocytes 
exposed for 48 hours to Aβ1-42 displayed a significant up-regulation of the 
transient outward potassium currents IA compared to control cells. The 
treatment with the selective blocker of KV3.4 channels, BDS-I (50nM), and the 
silencing of KV3.4 were able to prevent the current increase induced by the 
amyloid fragment. Thus we confirmed the contribution of KV3.4 function to the 
up-regulated IA currents in astrocytes exposed to Aβ1-42. To test the 
involvement of increased KV3.4 expression and activity in the early astrocytes 
activation in Tg2576 mouse brain, we explored in vivo whether the selective 
knockdown of the KV3.4 genes could affect astrocytes activation. To this aim, 
we silenced KV3.4 subunits with a selective siKV3.4 and analyzed GFAP 
protein levels in brain lysates from both Tg2576 and WT mice. Western Blot 
analysis revealed that GFAP protein levels were up-regulated in Tg2576 mice 
compared to age-matched WT and that the siKV3.4 significantly reduced 
astrocytes activation in Tg2576 mice. In astrocytes, the role of the interaction 
between a cytoskeleton protein, GFAP, and potassium channels remains still 
unclear. We could speculate that this link has a role in the channels trafficking 
to membrane. In fact, GFAP in astrocytes might promote channel addressing 
in precise domains of the membrane in order to facilitate the accumulation of 
KV3.4 channel and, in turn, the increase of potassium ions necessary to 
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activate specific cellular mechanisms. The position and localization of the 
cytoskeleton strongly reflect the corresponding position of the specific ionic 
gradients and the related binding proteins. Furthermore supporting evidence 
demonstrated the role of Ca2+ in the remodeling of the cytoskeleton (Hepler, 
2016), as well as K+ ions could promote the activation or inhibition of specific 
mechanisms in activated astrocytes. 
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